{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:39:38Z","timestamp":1794325178677,"version":"4.9.0"},"reference-count":347,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772740"],"award-info":[{"award-number":["81772740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173345"],"award-info":[{"award-number":["82173345"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972333"],"award-info":[{"award-number":["81972333"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372883"],"award-info":[{"award-number":["82372883"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022YFB4700904"],"award-info":[{"award-number":["2022YFB4700904"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic resistance remains a defining challenge in oncology, limiting the durability of current therapies and contributing to disease relapse and poor patient outcomes. This review systematically integrates recent progress in understanding the molecular, cellular, and ecological foundations of drug resistance across chemotherapy, targeted therapy, and immunotherapy. We delineate how genetic alterations, epigenetic reprogramming, post-translational modifications, and non-coding RNA networks cooperate with metabolic reprogramming and tumor microenvironment remodeling to sustain resistant phenotypes. The influence of the microbiome is highlighted as an emerging determinant of therapeutic response through immune modulation and metabolic cross-talk. By summarizing key regulatory circuits, We establishe a unified framework linking clonal evolution, metabolic adaptability, and tumor ecological dynamics. We further synthesizes novel therapeutic strategies that convert resistance mechanisms into therapeutic vulnerabilities, including synthetic lethality approaches, metabolic targeting, and disruption of stem cell and stromal niches. Advances in single-cell and spatial omics, liquid biopsy, and artificial intelligence are emphasized as transformative tools for early detection and real-time prediction of resistance evolution. This review also identifies major translational gaps in preclinical modeling and proposes precision oncology frameworks guided by evolutionary principles. By bridging mechanistic understanding with adaptive clinical design, this work provides an integrated roadmap for overcoming therapeutic resistance and achieving sustained, long-term cancer control.<\/jats:p>","DOI":"10.1186\/s43556-025-00352-w","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:59:15Z","timestamp":1763369955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Drug resistance in cancer: molecular mechanisms and emerging treatment strategies"],"prefix":"10.1186","volume":"6","author":[{"given":"Jinxin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiren","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-1832","authenticated-orcid":false,"given":"Linhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"3","key":"352_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"352_CR2","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029\u201330. https:\/\/doi.org\/10.1002\/cncr.33587.","journal-title":"Cancer"},{"key":"352_CR3","doi-asserted-by":"publisher","unstructured":"Matuszczak M, Kiljanczyk A, Salagierski M. Surgical Approach in Metastatic Renal Cell Carcinoma: A Literature Review. Cancers (Basel). 2023;15(6). https:\/\/doi.org\/10.3390\/cancers15061804.","DOI":"10.3390\/cancers15061804"},{"issue":"2","key":"352_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.suc.2018.12.008","volume":"99","author":"L Hickman","year":"2019","unstructured":"Hickman L, Contreras C. Gallbladder Cancer: Diagnosis, Surgical Management, and Adjuvant Therapies. Surg Clin North Am. 2019;99(2):337\u201355. https:\/\/doi.org\/10.1016\/j.suc.2018.12.008.","journal-title":"Surg Clin North Am"},{"issue":"2","key":"352_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/srao.2002.30823","volume":"12","author":"JA Meyerhardt","year":"2002","unstructured":"Meyerhardt JA, Fuchs CS. Chemotherapy options for gastric cancer. Semin Radiat Oncol. 2002;12(2):176\u201386. https:\/\/doi.org\/10.1053\/srao.2002.30823.","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"352_CR6","first-page":"155","volume":"103","author":"CEP Smith","year":"2021","unstructured":"Smith CEP, Prasad V. Targeted cancer therapies. Am Fam Physician. 2021;103(3):155\u201363.","journal-title":"Am Fam Physician"},{"key":"352_CR7","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476.","journal-title":"Front Immunol"},{"key":"352_CR8","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962. https:\/\/doi.org\/10.1016\/j.drup.2023.100962.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"352_CR9","doi-asserted-by":"publisher","first-page":"129915","DOI":"10.1016\/j.bbagen.2021.129915","volume":"1865","author":"X Gao","year":"2021","unstructured":"Gao X, Aguanno D, Board M, Callaghan R. Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer. Biochim Biophys Acta Gen Subj. 2021;1865(8):129915. https:\/\/doi.org\/10.1016\/j.bbagen.2021.129915.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"2","key":"352_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","volume":"126","author":"SK Herzog","year":"2022","unstructured":"Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126(2):174\u201386. https:\/\/doi.org\/10.1038\/s41416-021-01564-x.","journal-title":"Br J Cancer"},{"key":"352_CR11","doi-asserted-by":"publisher","first-page":"117880","DOI":"10.1016\/j.biopha.2025.117880","volume":"183","author":"D Keresztes","year":"2025","unstructured":"Keresztes D, Kerestely M, Szarka L, Kovacs BM, Schulc K, Veres DV, et al. Cancer drug resistance as learning of signaling networks. Biomed Pharmacother. 2025;183:117880. https:\/\/doi.org\/10.1016\/j.biopha.2025.117880.","journal-title":"Biomed Pharmacother"},{"key":"352_CR12","doi-asserted-by":"publisher","unstructured":"An J, Peng C, Tang H, Liu X, Peng F. New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. Int J Mol Sci. 2021;22(17). https:\/\/doi.org\/10.3390\/ijms22179644.","DOI":"10.3390\/ijms22179644"},{"issue":"6","key":"352_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022;22(6):323\u201339. https:\/\/doi.org\/10.1038\/s41568-022-00454-5.","journal-title":"Nat Rev Cancer"},{"key":"352_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"352_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun. 2023;43(3):297\u2013337. https:\/\/doi.org\/10.1002\/cac2.12387.","journal-title":"Cancer Commun"},{"issue":"9","key":"352_CR16","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","volume":"11","author":"M Kwon","year":"2021","unstructured":"Kwon M, An M, Klempner SJ, Lee H, Kim KM, Sa JK, et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov. 2021;11(9):2168\u201385. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0219.","journal-title":"Cancer Discov"},{"key":"352_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","volume":"65","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13\u201327. https:\/\/doi.org\/10.1016\/j.semcancer.2019.07.017.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"352_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339\u201348. https:\/\/doi.org\/10.15171\/apb.2017.041.","journal-title":"Adv Pharm Bull"},{"issue":"2","key":"352_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141\u201360. https:\/\/doi.org\/10.20517\/cdr.2019.10.","journal-title":"Cancer Drug Resist."},{"issue":"22","key":"352_CR20","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1158\/0008-5472.CAN-23-3374","volume":"84","author":"S Seyedi","year":"2024","unstructured":"Seyedi S, Harris VK, Kapsetaki SE, Narayanan S, Saha D, Compton Z, et al. Resistance management for cancer: lessons from farmers. Cancer Res. 2024;84(22):3715\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3374.","journal-title":"Cancer Res"},{"key":"352_CR21","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.ctarc.2025.100918","volume":"43","author":"HA Abouzeid","year":"2025","unstructured":"Abouzeid HA, Kassem L, Liu X, Abuelhana A. Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies. Cancer Treatment and Research Communications. 2025;43:100918. https:\/\/doi.org\/10.1016\/j.ctarc.2025.100918.","journal-title":"Cancer Treatment and Research Communications"},{"key":"352_CR22","doi-asserted-by":"publisher","unstructured":"Fahmy SA, Mahdy NK, Mohamed AH, Mokhtar FA, Youness RA. Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles. Int J Mol Sci. 2024;25(4). https:\/\/doi.org\/10.3390\/ijms25042070.","DOI":"10.3390\/ijms25042070"},{"issue":"5","key":"352_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12032-025-02712-6","volume":"42","author":"D Purnomosari","year":"2025","unstructured":"Purnomosari D, Nabila BZ, Widyarini S, Mustofa. Targeting immune cells in tumor microenvironment in triple negative breast cancer therapy: future perspective to overcome doxorubicin resistance and toxicity. Med Oncol. 2025;42(5):150. https:\/\/doi.org\/10.1007\/s12032-025-02712-6.","journal-title":"Med Oncol"},{"issue":"8","key":"352_CR24","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1200\/JCO.1994.12.8.1639","volume":"12","author":"K Porkka","year":"1994","unstructured":"Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhonen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol. 1994;12(8):1639\u201347. https:\/\/doi.org\/10.1200\/JCO.1994.12.8.1639.","journal-title":"J Clin Oncol"},{"issue":"11","key":"352_CR25","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","volume":"12","author":"M Anurag","year":"2022","unstructured":"Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, et al. Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer. Cancer Discov. 2022;12(11):2586\u2013605. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0200.","journal-title":"Cancer Discov"},{"issue":"9","key":"352_CR26","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/cas.14532","volume":"111","author":"S Blondy","year":"2020","unstructured":"Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142\u201354. https:\/\/doi.org\/10.1111\/cas.14532.","journal-title":"Cancer Sci"},{"key":"352_CR27","doi-asserted-by":"publisher","first-page":"114986","DOI":"10.1016\/j.biopha.2023.114986","volume":"164","author":"J Yuan","year":"2023","unstructured":"Yuan J, Khan SU, Yan J, Lu J, Yang C, Tong Q. Baicalin enhances the efficacy of 5-fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis. Biomed Pharmacother. 2023;164:114986. https:\/\/doi.org\/10.1016\/j.biopha.2023.114986.","journal-title":"Biomed Pharmacother"},{"key":"352_CR28","doi-asserted-by":"publisher","first-page":"101846","DOI":"10.1016\/j.tranon.2023.101846","volume":"40","author":"M Hashemi","year":"2024","unstructured":"Hashemi M, Esbati N, Rashidi M, Gholami S, Raesi R, Bidoki SS, et al. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer. Transl Oncol. 2024;40:101846. https:\/\/doi.org\/10.1016\/j.tranon.2023.101846.","journal-title":"Transl Oncol"},{"issue":"6","key":"352_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s10120-021-01206-4","volume":"24","author":"K Harada","year":"2021","unstructured":"Harada K, Sakamoto N, Ukai S, Yamamoto Y, Pham QT, Taniyama D, et al. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance. Gastric Cancer. 2021;24(6):1264\u201377. https:\/\/doi.org\/10.1007\/s10120-021-01206-4.","journal-title":"Gastric Cancer"},{"key":"352_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076026","author":"MT Masucci","year":"2023","unstructured":"Masucci MT, Motti ML, Minopoli M, Di Carluccio G, Carriero MV. Emerging targeted therapeutic strategies to overcome imatinib resistance of gastrointestinal stromal tumors. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076026.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"352_CR31","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","volume":"19","author":"AD Seidman","year":"2001","unstructured":"Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19(10):2587\u201395. https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2587.","journal-title":"J Clin Oncol"},{"issue":"10","key":"352_CR32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411\u201320. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2187.","journal-title":"JAMA Oncol"},{"issue":"12","key":"352_CR33","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1093\/annonc\/mdt406","volume":"24","author":"FA Raja","year":"2013","unstructured":"Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol. 2013;24(12):3028\u201334. https:\/\/doi.org\/10.1093\/annonc\/mdt406.","journal-title":"Ann Oncol"},{"issue":"1","key":"352_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"327","key":"352_CR35","doi-asserted-by":"publisher","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","volume":"8","author":"PM Enriquez-Navas","year":"2016","unstructured":"Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016;8(327):327ra24. https:\/\/doi.org\/10.1126\/scitranslmed.aad7842.","journal-title":"Sci Transl Med"},{"key":"352_CR36","doi-asserted-by":"publisher","first-page":"216205","DOI":"10.1016\/j.canlet.2023.216205","volume":"564","author":"J Lu","year":"2023","unstructured":"Lu J, Li J, Lin Z, Li H, Lou L, Ding W, et al. Reprogramming of TAMs via the STAT3\/CD47-SIRP\u03b1 axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Lett. 2023;564:216205. https:\/\/doi.org\/10.1016\/j.canlet.2023.216205.","journal-title":"Cancer Lett"},{"issue":"1","key":"352_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther. 2023;8(1):113. https:\/\/doi.org\/10.1038\/s41392-023-01383-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"352_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"ZF Lim","year":"2019","unstructured":"Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134. https:\/\/doi.org\/10.1186\/s13045-019-0818-2.","journal-title":"J Hematol Oncol"},{"key":"352_CR39","doi-asserted-by":"publisher","unstructured":"Hass R, von der Ohe J, Ungefroren H. Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness. Cancers (Basel). 2020;12(12). https:\/\/doi.org\/10.3390\/cancers12123716.","DOI":"10.3390\/cancers12123716"},{"issue":"1","key":"352_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19(1):39\u201356. https:\/\/doi.org\/10.1038\/s41573-019-0044-1.","journal-title":"Nat Rev Drug Discov"},{"key":"352_CR41","doi-asserted-by":"publisher","first-page":"105583","DOI":"10.1016\/j.phrs.2021.105583","volume":"167","author":"RF Dong","year":"2021","unstructured":"Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research. Pharmacol Res. 2021;167:105583. https:\/\/doi.org\/10.1016\/j.phrs.2021.105583.","journal-title":"Pharmacol Res"},{"issue":"1","key":"352_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15(1):173. https:\/\/doi.org\/10.1186\/s13045-022-01391-4.","journal-title":"J Hematol Oncol"},{"issue":"suppl_1","key":"352_CR43","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx703.","journal-title":"Ann Oncol"},{"issue":"10","key":"352_CR44","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1111\/cas.14593","volume":"111","author":"A Nishiyama","year":"2020","unstructured":"Nishiyama A, Takeuchi S, Adachi Y, Otani S, Tanimoto A, Sasaki M, et al. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Cancer Sci. 2020;111(10):3813\u201323. https:\/\/doi.org\/10.1111\/cas.14593.","journal-title":"Cancer Sci"},{"issue":"10","key":"352_CR45","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","volume":"26","author":"D Planchard","year":"2015","unstructured":"Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26(10):2073\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdv319.","journal-title":"Ann Oncol"},{"issue":"5","key":"352_CR46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s12276-024-01221-2","volume":"56","author":"W Park","year":"2024","unstructured":"Park W, Wei S, Xie CL, Han JH, Kim BS, Kim B, et al. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer. Exp Mol Med. 2024;56(5):1137\u201349. https:\/\/doi.org\/10.1038\/s12276-024-01221-2.","journal-title":"Exp Mol Med"},{"key":"352_CR47","doi-asserted-by":"publisher","first-page":"1020888","DOI":"10.3389\/fmolb.2022.1020888","volume":"9","author":"SK Hsu","year":"2022","unstructured":"Hsu SK, Jadhao M, Liao WT, Chang WT, Hung CT, Chiu CC. Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: tumour microenvironment components. Front Mol Biosci. 2022;9:1020888. https:\/\/doi.org\/10.3389\/fmolb.2022.1020888.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"352_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol Med. 2023;29(6):439\u201353. https:\/\/doi.org\/10.1016\/j.molmed.2023.03.002.","journal-title":"Trends Mol Med"},{"key":"352_CR49","doi-asserted-by":"publisher","unstructured":"Cannone S, Greco MR, Carvalho TMA, Guizouarn H, Soriani O, Di Molfetta D, et al. Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition. Cancers (Basel). 2022;14(15). https:\/\/doi.org\/10.3390\/cancers14153737.","DOI":"10.3390\/cancers14153737"},{"issue":"3","key":"352_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00401-018-1815-1","volume":"135","author":"S Liebner","year":"2018","unstructured":"Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 2018;135(3):311\u201336. https:\/\/doi.org\/10.1007\/s00401-018-1815-1.","journal-title":"Acta Neuropathol"},{"key":"352_CR51","doi-asserted-by":"publisher","unstructured":"Gomez-Zepeda D, Taghi M, Scherrmann JM, Decleves X, Menet MC. ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. Pharmaceutics. 2019;12(1). https:\/\/doi.org\/10.3390\/pharmaceutics12010020.","DOI":"10.3390\/pharmaceutics12010020"},{"key":"352_CR52","doi-asserted-by":"publisher","first-page":"114442","DOI":"10.1016\/j.ejmech.2022.114442","volume":"238","author":"YL Pan","year":"2022","unstructured":"Pan YL, Zeng SX, Hao RR, Liang MH, Shen ZR, Huang WH. The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. Eur J Med Chem. 2022;238:114442. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114442.","journal-title":"Eur J Med Chem"},{"key":"352_CR53","doi-asserted-by":"publisher","unstructured":"El-Tanani M, Nsairat H, Matalka, II, Lee YF, Rizzo M, Aljabali AA, et al. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol Res Pract. 2024;254(155161). https:\/\/doi.org\/10.1016\/j.prp.2024.155161.","DOI":"10.1016\/j.prp.2024.155161"},{"key":"352_CR54","doi-asserted-by":"publisher","first-page":"156062","DOI":"10.1016\/j.cyto.2022.156062","volume":"161","author":"O Aksoy","year":"2023","unstructured":"Aksoy O, Lind J, Sunder-Plassmann V, Vallet S, Podar K. Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): therapeutic implications. Cytokine. 2023;161:156062. https:\/\/doi.org\/10.1016\/j.cyto.2022.156062.","journal-title":"Cytokine"},{"issue":"12","key":"352_CR55","doi-asserted-by":"publisher","first-page":"e33091","DOI":"10.1016\/j.heliyon.2024.e33091","volume":"10","author":"K Bhowmick","year":"2024","unstructured":"Bhowmick K, von Suskil M, Al-Odat OS, Elbezanti WO, Jonnalagadda SC, Budak-Alpdogan T, et al. Pathways to therapy resistance: the sheltering effect of the bone marrow microenvironment to multiple myeloma cells. Heliyon. 2024;10(12):e33091. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33091.","journal-title":"Heliyon"},{"issue":"9","key":"352_CR56","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337. https:\/\/doi.org\/10.1038\/s41416-019-0573-8.","journal-title":"Br J Cancer"},{"issue":"8","key":"352_CR57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499\u2013514. https:\/\/doi.org\/10.1038\/s41571-022-00639-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"352_CR58","doi-asserted-by":"publisher","unstructured":"Guaitoli G, Bertolini F, Bettelli S, Manfredini S, Maur M, Trudu L, et al. Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations. Int J Mol Sci. 2021;22(23). https:\/\/doi.org\/10.3390\/ijms222312867..","DOI":"10.3390\/ijms222312867."},{"key":"352_CR59","doi-asserted-by":"publisher","unstructured":"Rivas S, Marin A, Samtani S, Gonzalez-Feliu E, Armisen R. MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies. Int J Mol Sci. 2022;23(22). https:\/\/doi.org\/10.3390\/ijms232213898.","DOI":"10.3390\/ijms232213898"},{"key":"352_CR60","doi-asserted-by":"publisher","first-page":"1006429","DOI":"10.3389\/fonc.2022.1006429","volume":"12","author":"ZH Wang","year":"2022","unstructured":"Wang ZH, Zheng ZQ, Jia SC, Liu SN, Xiao XF, Chen GY, et al. Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents. Front Oncol. 2022;12:1006429. https:\/\/doi.org\/10.3389\/fonc.2022.1006429.","journal-title":"Front Oncol"},{"issue":"9","key":"352_CR61","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11912-023-01436-y","volume":"25","author":"A Di Federico","year":"2023","unstructured":"Di Federico A, Ricciotti I, Favorito V, Michelina SV, Scaparone P, Metro G, et al. Resistance to KRAS G12C inhibition in non-small cell lung cancer. Curr Oncol Rep. 2023;25(9):1017\u201329. https:\/\/doi.org\/10.1007\/s11912-023-01436-y.","journal-title":"Curr Oncol Rep"},{"key":"352_CR62","doi-asserted-by":"publisher","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","volume":"92","author":"E Kun","year":"2021","unstructured":"Kun E, Tsang YTM, Ng CW, Gershenson DM, Wong KK. MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev. 2021;92:102137. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102137.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"352_CR63","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","volume":"48","author":"FH Shah","year":"2025","unstructured":"Shah FH, Nam YS, Bang JY, Hwang IS, Kim DH, Ki M, et al. Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance. Arch Pharm Res. 2025;48(5):404\u201325. https:\/\/doi.org\/10.1007\/s12272-025-01545-1.","journal-title":"Arch Pharm Res"},{"issue":"2","key":"352_CR64","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1210\/endrev\/bnac025","volume":"44","author":"RA Toledo","year":"2023","unstructured":"Toledo RA, Jimenez C, Armaiz-Pena G, Arenillas C, Capdevila J, Dahia PLM. Hypoxia-Inducible Factor 2 Alpha (HIF2alpha) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocr Rev. 2023;44(2):312\u201322. https:\/\/doi.org\/10.1210\/endrev\/bnac025.","journal-title":"Endocr Rev"},{"issue":"12","key":"352_CR65","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773\u201391. https:\/\/doi.org\/10.1038\/s41571-021-00532-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"352_CR66","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1002\/1878-0261.13224","volume":"16","author":"JS Baxter","year":"2022","unstructured":"Baxter JS, Zatreanu D, Pettitt SJ, Lord CJ. Resistance to DNA repair inhibitors in cancer. Mol Oncol. 2022;16(21):3811\u201327. https:\/\/doi.org\/10.1002\/1878-0261.13224.","journal-title":"Mol Oncol"},{"key":"352_CR67","doi-asserted-by":"publisher","first-page":"931462","DOI":"10.3389\/fonc.2022.931462","volume":"12","author":"X Zhuang","year":"2022","unstructured":"Zhuang X, Pei HZ, Li T, Huang J, Guo Y, Zhao Y, et al. The molecular mechanisms of resistance to IDH inhibitors in acute myeloid leukemia. Front Oncol. 2022;12:931462. https:\/\/doi.org\/10.3389\/fonc.2022.931462.","journal-title":"Front Oncol"},{"issue":"1","key":"352_CR68","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang ZQ, Zhang ZC, Wu YY, Pi YN, Lou SH, Liu TB, et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal Transduct Target Ther. 2023;8(1):420. https:\/\/doi.org\/10.1038\/s41392-023-01647-6.","journal-title":"Signal Transduct Target Ther"},{"key":"352_CR69","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5184","author":"J Huang","year":"2022","unstructured":"Huang J, Zheng L, Sun Z, Li J. CDK4\/6 inhibitor resistance mechanisms and treatment strategies (Review). Int J Mol Med. 2022. https:\/\/doi.org\/10.3892\/ijmm.2022.5184.","journal-title":"Int J Mol Med"},{"key":"352_CR70","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672. https:\/\/doi.org\/10.3389\/fcell.2020.00672.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"352_CR71","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.21873\/anticanres.14945","volume":"41","author":"G Rigakos","year":"2021","unstructured":"Rigakos G, Razis E, Koliou GA, Oikonomopoulos G, Tsolaki E, Sperinde J, et al. Evaluation of the role of p95 HER2 isoform in trastuzumab efficacy in metastatic breast cancer. Anticancer Res. 2021;41(4):1793\u2013802. https:\/\/doi.org\/10.21873\/anticanres.14945.","journal-title":"Anticancer Res"},{"key":"352_CR72","doi-asserted-by":"publisher","first-page":"217112","DOI":"10.1016\/j.canlet.2024.217112","volume":"598","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhang L, He Y, Jiang D, Sun J, Luo Q, et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett. 2024;598:217112. https:\/\/doi.org\/10.1016\/j.canlet.2024.217112.","journal-title":"Cancer Lett"},{"issue":"10","key":"352_CR73","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","volume":"25","author":"J Wolf","year":"2024","unstructured":"Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024;25(10):1357\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(24)00441-8.","journal-title":"Lancet Oncol"},{"issue":"6","key":"352_CR74","doi-asserted-by":"publisher","first-page":"484","DOI":"10.20892\/j.issn.2095-3941.2024.0044","volume":"21","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Shen L, Peng Z. Advances in MET tyrosine kinase inhibitors in gastric cancer. Cancer Biol Med. 2024;21(6):484\u201398. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0044.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"352_CR75","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4143\/crt.2018.052","volume":"51","author":"S Kim","year":"2019","unstructured":"Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, et al. Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib. Cancer Res Treat. 2019;51(3):951\u201362. https:\/\/doi.org\/10.4143\/crt.2018.052.","journal-title":"Cancer Res Treat"},{"key":"352_CR76","doi-asserted-by":"publisher","first-page":"112919","DOI":"10.1016\/j.ejca.2023.05.007","volume":"189","author":"R Han","year":"2023","unstructured":"Han R, Guo H, Shi J, Wang H, Zhao S, Jia Y, et al. Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer. Eur J Cancer. 2023;189:112919. https:\/\/doi.org\/10.1016\/j.ejca.2023.05.007.","journal-title":"Eur J Cancer"},{"issue":"7","key":"352_CR77","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523\u201345. https:\/\/doi.org\/10.1016\/j.it.2022.04.010.","journal-title":"Trends Immunol"},{"key":"352_CR78","doi-asserted-by":"publisher","unstructured":"Rai V. Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives. Biomolecules. 2025;15(6). https:\/\/doi.org\/10.3390\/biom15060751.","DOI":"10.3390\/biom15060751"},{"issue":"10","key":"352_CR79","doi-asserted-by":"publisher","first-page":"101199","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan NP. Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach. Cell Rep Med. 2023;4(10):101199. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101199.","journal-title":"Cell Rep Med"},{"issue":"4","key":"352_CR80","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1002\/imt2.147","volume":"2","author":"J Meng","year":"2023","unstructured":"Meng J, Jiang A, Lu X, Gu D, Ge Q, Bai S, et al. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy. Imeta. 2023;2(4):e147. https:\/\/doi.org\/10.1002\/imt2.147.","journal-title":"Imeta"},{"issue":"2","key":"352_CR81","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42(2):209-24 e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.013.","journal-title":"Cancer Cell"},{"issue":"10105","key":"352_CR82","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X.","journal-title":"Lancet"},{"issue":"1","key":"352_CR83","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11912-020-00993-w","volume":"23","author":"V Agrawal","year":"2020","unstructured":"Agrawal V, Benjamin KT, Ko EC. Radiotherapy and immunotherapy combinations for lung cancer. Curr Oncol Rep. 2020;23(1):4. https:\/\/doi.org\/10.1007\/s11912-020-00993-w.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"352_CR84","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398\u2013405. https:\/\/doi.org\/10.1200\/JCO.2010.29.5865.","journal-title":"J Clin Oncol"},{"issue":"1","key":"352_CR85","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12(1):3528. https:\/\/doi.org\/10.1038\/s41467-021-23793-7.","journal-title":"Nat Commun"},{"issue":"1","key":"352_CR86","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13058-017-0900-z","volume":"19","author":"T Baldassarre","year":"2017","unstructured":"Baldassarre T, Truesdell P, Craig AW. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res. 2017;19(1):110. https:\/\/doi.org\/10.1186\/s13058-017-0900-z.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"352_CR87","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","volume":"17","author":"M Sung","year":"2018","unstructured":"Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, et al. Caveolae-mediated endocytosis as a novel mechanism of resistance to Trastuzumab emtansine (T-DM1). Mol Cancer Ther. 2018;17(1):243\u201353. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0403.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"352_CR88","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","volume":"77","author":"C Rios-Luci","year":"2017","unstructured":"Rios-Luci C, Garcia-Alonso S, Diaz-Rodriguez E, Nadal-Serrano M, Arribas J, Ocana A, et al. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 2017;77(17):4639\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3127.","journal-title":"Cancer Res"},{"issue":"7","key":"352_CR89","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13253","volume":"108","author":"H Wang","year":"2017","unstructured":"Wang H, Wang W, Xu Y, Yang Y, Chen X, Quan H, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 2017;108(7):1458\u201368. https:\/\/doi.org\/10.1111\/cas.13253.","journal-title":"Cancer Sci"},{"issue":"14","key":"352_CR90","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","volume":"21","author":"SF Yu","year":"2015","unstructured":"Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res. 2015;21(14):3298\u2013306. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2035.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"352_CR91","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, et al. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discov. 2021;11(10):2436\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0702.","journal-title":"Cancer Discov"},{"key":"352_CR92","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59:100796. https:\/\/doi.org\/10.1016\/j.drup.2021.100796.","journal-title":"Drug Resist Updat"},{"key":"352_CR93","doi-asserted-by":"publisher","first-page":"656364","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12:656364. https:\/\/doi.org\/10.3389\/fimmu.2021.656364.","journal-title":"Front Immunol"},{"issue":"2","key":"352_CR94","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"352_CR95","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell. 2020;37(4):471\u201384. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.007.","journal-title":"Cancer Cell"},{"issue":"1","key":"352_CR96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41576-020-0265-5","volume":"22","author":"AS Nam","year":"2021","unstructured":"Nam AS, Chaligne R, Landau DA. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. Nat Rev Genet. 2021;22(1):3\u201318. https:\/\/doi.org\/10.1038\/s41576-020-0265-5.","journal-title":"Nat Rev Genet"},{"key":"352_CR97","doi-asserted-by":"publisher","unstructured":"Shklovskaya E, Rizos H. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. Int J Mol Sci. 2020;21(19). https:\/\/doi.org\/10.3390\/ijms21197139.","DOI":"10.3390\/ijms21197139"},{"key":"352_CR98","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.drup.2024.101195","volume":"79","author":"X Ma","year":"2025","unstructured":"Ma X, Xu J, Wang Y, Fleishman JS, Bing H, Yu B, et al. Research progress on gene mutations and drug resistance in leukemia. Drug Resist Updat. 2025;79:101195. https:\/\/doi.org\/10.1016\/j.drup.2024.101195.","journal-title":"Drug Resist Updat"},{"key":"352_CR99","doi-asserted-by":"publisher","unstructured":"Qin K, Hong L, Zhang J, Le X. MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities. Cancers (Basel). 2023;15(3). https:\/\/doi.org\/10.3390\/cancers15030612.","DOI":"10.3390\/cancers15030612"},{"issue":"12","key":"352_CR100","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731\u201347. https:\/\/doi.org\/10.1038\/s41571-018-0113-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"352_CR101","doi-asserted-by":"publisher","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020;21(9). https:\/\/doi.org\/10.3390\/ijms21093233.","DOI":"10.3390\/ijms21093233"},{"issue":"1","key":"352_CR102","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021;14(1):157. https:\/\/doi.org\/10.1186\/s13045-021-01169-0.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"352_CR103","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","volume":"8","author":"K Hientz","year":"2017","unstructured":"Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921\u201346. https:\/\/doi.org\/10.18632\/oncotarget.13475.","journal-title":"Oncotarget"},{"issue":"7","key":"352_CR104","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452\u201364. https:\/\/doi.org\/10.1038\/s41568-018-0005-8.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"352_CR105","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0006-2952(92)90666-7","volume":"43","author":"IB Roninson","year":"1992","unstructured":"Roninson IB. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol. 1992;43(1):95\u2013102. https:\/\/doi.org\/10.1016\/0006-2952(92)90666-7.","journal-title":"Biochem Pharmacol"},{"key":"352_CR106","doi-asserted-by":"publisher","unstructured":"Jensen NF, Agama K, Roy A, Smith DH, Pfister TD, Romer MU, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. J Exp Clin Cancer Res. 2016;35(56). https:\/\/doi.org\/10.1186\/s13046-016-0335-x.","DOI":"10.1186\/s13046-016-0335-x"},{"key":"352_CR107","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1476-4598-10-64","volume":"10","author":"C Gongora","year":"2011","unstructured":"Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, et al. New topoisomerase I mutations are associated with resistance to camptothecin. Mol Cancer. 2011;10:64. https:\/\/doi.org\/10.1186\/1476-4598-10-64.","journal-title":"Mol Cancer"},{"issue":"3","key":"352_CR108","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrc2803","volume":"10","author":"M Kavallaris","year":"2010","unstructured":"Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194\u2013204. https:\/\/doi.org\/10.1038\/nrc2803.","journal-title":"Nat Rev Cancer"},{"key":"352_CR109","doi-asserted-by":"publisher","first-page":"100881","DOI":"10.1016\/j.drup.2022.100881","volume":"65","author":"ER Smith","year":"2022","unstructured":"Smith ER, Wang JQ, Yang DH, Xu XX. Paclitaxel resistance related to nuclear envelope structural sturdiness. Drug Resist Updat. 2022;65:100881. https:\/\/doi.org\/10.1016\/j.drup.2022.100881.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"352_CR110","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","volume":"25","author":"A Soragni","year":"2025","unstructured":"Soragni A, Knudsen ES, O\u2019Connor TN, Tognon CE, Tyner JW, Gini B, et al. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer. 2025;25(8):613\u201333. https:\/\/doi.org\/10.1038\/s41568-025-00824-9.","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"352_CR111","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","volume":"14","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008;14(14):4392\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0117.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"352_CR112","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006.","journal-title":"Cancer Cell"},{"issue":"7","key":"352_CR113","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","volume":"28","author":"K Haratani","year":"2017","unstructured":"Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017;28(7):1532\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx183.","journal-title":"Ann Oncol"},{"issue":"7605","key":"352_CR114","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129\u201332. https:\/\/doi.org\/10.1038\/nature17960.","journal-title":"Nature"},{"issue":"24","key":"352_CR115","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","volume":"70","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010;70(24):10038\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2956.","journal-title":"Cancer Res"},{"issue":"Suppl 3","key":"352_CR116","doi-asserted-by":"publisher","first-page":"iii42","DOI":"10.1093\/annonc\/mdw305","volume":"27 Suppl 3","author":"I Dagogo-Jack","year":"2016","unstructured":"Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016;27 Suppl 3(Suppl 3):iii42\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdw305.","journal-title":"Ann Oncol"},{"key":"352_CR117","doi-asserted-by":"publisher","first-page":"107123","DOI":"10.1016\/j.phrs.2024.107123","volume":"202","author":"X Liu","year":"2024","unstructured":"Liu X, Mei W, Zhang P, Zeng C. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities. Pharmacol Res. 2024;202:107123. https:\/\/doi.org\/10.1016\/j.phrs.2024.107123.","journal-title":"Pharmacol Res"},{"key":"352_CR118","doi-asserted-by":"publisher","first-page":"e2100370","DOI":"10.1200\/PO.21.00370","volume":"6","author":"AR Rasti","year":"2022","unstructured":"Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol. 2022;6:e2100370. https:\/\/doi.org\/10.1200\/PO.21.00370.","journal-title":"JCO Precis Oncol"},{"issue":"7538","key":"352_CR119","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature. 2015;518(7538):240\u20134. https:\/\/doi.org\/10.1038\/nature13948.","journal-title":"Nature"},{"issue":"10","key":"352_CR120","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","volume":"27","author":"JJ Lin","year":"2021","unstructured":"Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, et al. Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer. Clin Cancer Res. 2021;27(10):2899\u2013909. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0032.","journal-title":"Clin Cancer Res"},{"key":"352_CR121","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.canlet.2019.12.015","volume":"472","author":"C Lin","year":"2020","unstructured":"Lin C, Ren Z, Yang X, Yang R, Chen Y, Liu Z, et al. Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. Cancer Lett. 2020;472:81\u201396. https:\/\/doi.org\/10.1016\/j.canlet.2019.12.015.","journal-title":"Cancer Lett"},{"issue":"9","key":"352_CR122","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","volume":"3","author":"S Deng","year":"2022","unstructured":"Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, et al. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat Cancer. 2022;3(9):1071\u201387. https:\/\/doi.org\/10.1038\/s43018-022-00431-9.","journal-title":"Nat Cancer"},{"issue":"9","key":"352_CR123","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1604958.","journal-title":"N Engl J Med"},{"issue":"6230","key":"352_CR124","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Science"},{"issue":"2","key":"352_CR125","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1223.","journal-title":"Cancer Discov"},{"key":"352_CR126","doi-asserted-by":"publisher","unstructured":"IFNgamma Mutations Prompt CTLA-4 Inhibitor Resistance. Cancer Discov. 2017;7(1):OF3. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2016-148.","DOI":"10.1158\/2159-8290.CD-NB2016-148"},{"issue":"2","key":"352_CR127","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397-404 e9. https:\/\/doi.org\/10.1016\/j.cell.2016.08.069.","journal-title":"Cell"},{"issue":"1","key":"352_CR128","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41422-023-00909-w","volume":"34","author":"LP Ge","year":"2024","unstructured":"Ge LP, Jin X, Ma D, Wang ZY, Liu CL, Zhou CZ, et al. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell Res. 2024;34(1):58\u201375. https:\/\/doi.org\/10.1038\/s41422-023-00909-w.","journal-title":"Cell Res"},{"key":"352_CR129","doi-asserted-by":"publisher","unstructured":"Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, et al. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022;132(22). https:\/\/doi.org\/10.1172\/JCI159628.","DOI":"10.1172\/JCI159628"},{"key":"352_CR130","doi-asserted-by":"publisher","unstructured":"Adhikari S, Bhattacharya A, Adhikary S, Singh V, Gadad SS, Roy S, et al. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022;42(4).\u00a0https:\/\/doi.org\/10.1042\/BSR20211812.","DOI":"10.1042\/BSR20211812"},{"issue":"14","key":"352_CR131","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.7150\/thno.42523","volume":"10","author":"D Ravindran Menon","year":"2020","unstructured":"Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics. 2020;10(14):6261\u201377. https:\/\/doi.org\/10.7150\/thno.42523.","journal-title":"Theranostics"},{"issue":"1","key":"352_CR132","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327. https:\/\/doi.org\/10.1016\/j.cell.2012.06.013.","journal-title":"Cell"},{"issue":"6","key":"352_CR133","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","volume":"152","author":"TI Lee","year":"2013","unstructured":"Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237\u201351. https:\/\/doi.org\/10.1016\/j.cell.2013.02.014.","journal-title":"Cell"},{"key":"352_CR134","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-cellbio-100818-125127","volume":"35","author":"B Aydin","year":"2019","unstructured":"Aydin B, Mazzoni EO. Cell reprogramming: the many roads to success. Annu Rev Cell Dev Biol. 2019;35:433. https:\/\/doi.org\/10.1146\/annurev-cellbio-100818-125127.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"Suppl 1","key":"352_CR135","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.ctrv.2011.04.010","volume":"37","author":"AR Poetsch","year":"2011","unstructured":"Poetsch AR, Plass C. Transcriptional regulation by DNA methylation. Cancer Treat Rev. 2011;37(Suppl 1):S8-12. https:\/\/doi.org\/10.1016\/j.ctrv.2011.04.010.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"352_CR136","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s13238-020-00733-7","volume":"11","author":"LY Zhao","year":"2020","unstructured":"Zhao LY, Song J, Liu Y, Song CX, Yi C. Mapping the epigenetic modifications of DNA and RNA. Protein Cell. 2020;11(11):792\u2013808. https:\/\/doi.org\/10.1007\/s13238-020-00733-7.","journal-title":"Protein Cell"},{"issue":"5","key":"352_CR137","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.molcel.2014.05.015","volume":"54","author":"H Easwaran","year":"2014","unstructured":"Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716\u201327. https:\/\/doi.org\/10.1016\/j.molcel.2014.05.015.","journal-title":"Mol Cell"},{"issue":"7","key":"352_CR138","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer. 2020;6(7):580\u201392. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.003.","journal-title":"Trends Cancer"},{"issue":"11","key":"352_CR139","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","volume":"19","author":"SJ Hogg","year":"2020","unstructured":"Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020;19(11):776\u2013800. https:\/\/doi.org\/10.1038\/s41573-020-0077-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"352_CR140","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021;20(1):171. https:\/\/doi.org\/10.1186\/s12943-021-01464-x.","journal-title":"Mol Cancer"},{"issue":"7","key":"352_CR141","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-22-0784","volume":"29","author":"G Micevic","year":"2023","unstructured":"Micevic G, Bosenberg MW, Yan Q. The crossroads of cancer epigenetics and immune checkpoint therapy. Clin Cancer Res. 2023;29(7):1173\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0784.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"352_CR142","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7150\/ijbs.11218","volume":"11","author":"H Meng","year":"2015","unstructured":"Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi Y, et al. DNA methylation, its mediators and genome integrity. Int J Biol Sci. 2015;11(5):604\u201317. https:\/\/doi.org\/10.7150\/ijbs.11218.","journal-title":"Int J Biol Sci"},{"key":"352_CR143","doi-asserted-by":"publisher","first-page":"108640","DOI":"10.1016\/j.pharmthera.2024.108640","volume":"258","author":"AV Lee","year":"2024","unstructured":"Lee AV, Nestler KA, Chiappinelli KB. Therapeutic targeting of DNA methylation alterations in cancer. Pharmacol Ther. 2024;258:108640. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108640.","journal-title":"Pharmacol Ther"},{"issue":"42","key":"352_CR144","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1038\/onc.2011.611","volume":"31","author":"C Zeller","year":"2012","unstructured":"Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012;31(42):4567\u201376. https:\/\/doi.org\/10.1038\/onc.2011.611.","journal-title":"Oncogene"},{"issue":"21","key":"352_CR145","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.7150\/thno.35572","volume":"9","author":"T Zhao","year":"2019","unstructured":"Zhao T, Bao Y, Gan X, Wang J, Chen Q, Dai Z, et al. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma. Theranostics. 2019;9(21):6175\u201390. https:\/\/doi.org\/10.7150\/thno.35572.","journal-title":"Theranostics"},{"issue":"108","key":"352_CR146","doi-asserted-by":"publisher","first-page":"eado3485","DOI":"10.1126\/sciimmunol.ado3485","volume":"10","author":"J Liang","year":"2025","unstructured":"Liang J, Liao J, Chang R, Jia W, Li G, Chen Z, et al. Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma. Sci Immunol. 2025;10(108):eado3485. https:\/\/doi.org\/10.1126\/sciimmunol.ado3485.","journal-title":"Sci Immunol"},{"key":"352_CR147","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.semcancer.2020.07.015","volume":"83","author":"ME Neganova","year":"2022","unstructured":"Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. Semin Cancer Biol. 2022;83:452. https:\/\/doi.org\/10.1016\/j.semcancer.2020.07.015.","journal-title":"Semin Cancer Biol"},{"key":"352_CR148","doi-asserted-by":"publisher","first-page":"102324","DOI":"10.1016\/j.arr.2024.102324","volume":"98","author":"A Zhao","year":"2024","unstructured":"Zhao A, Xu W, Han R, Wei J, Yu Q, Wang M, et al. Role of histone modifications in neurogenesis and neurodegenerative disease development. Ageing Res Rev. 2024;98:102324. https:\/\/doi.org\/10.1016\/j.arr.2024.102324.","journal-title":"Ageing Res Rev"},{"issue":"21","key":"352_CR149","doi-asserted-by":"publisher","first-page":"e2114324119","DOI":"10.1073\/pnas.2114324119","volume":"119","author":"M Baratchian","year":"2022","unstructured":"Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, Yuan W, Berk M, et al. H3k9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer. Proc Natl Acad Sci U S A. 2022;119(21):e2114324119. https:\/\/doi.org\/10.1073\/pnas.2114324119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"352_CR150","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1186\/s12885-024-12624-9","volume":"24","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wu S, Han Y, Shi H, Yuan J, Cui W. LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation. BMC Cancer. 2024;24(1):848. https:\/\/doi.org\/10.1186\/s12885-024-12624-9.","journal-title":"BMC Cancer"},{"issue":"3","key":"352_CR151","doi-asserted-by":"publisher","first-page":"e70272","DOI":"10.1002\/ctm2.70272","volume":"15","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wu H, Li Z, Chen Z, Feng A, Chu Y, et al. PADI4 facilitates stem-like properties and cisplatin resistance through upregulating PRMT2\/IDs family in oesophageal squamous cell carcinoma. Clin Transl Med. 2025;15(3):e70272. https:\/\/doi.org\/10.1002\/ctm2.70272.","journal-title":"Clin Transl Med"},{"issue":"40","key":"352_CR152","doi-asserted-by":"publisher","first-page":"e2509255122","DOI":"10.1073\/pnas.2509255122","volume":"122","author":"S Chen","year":"2025","unstructured":"Chen S, Zhong M, Wang X, Su Y, Zhao Y, Wang S, et al. Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer. Proc Natl Acad Sci USA. 2025;122(40):e2509255122. https:\/\/doi.org\/10.1073\/pnas.2509255122.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"352_CR153","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/15548627.2023.2249762","volume":"20","author":"W Li","year":"2024","unstructured":"Li W, Zhou C, Yu L, Hou Z, Liu H, Kong L, et al. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024;20(1):114\u201330. https:\/\/doi.org\/10.1080\/15548627.2023.2249762.","journal-title":"Autophagy"},{"issue":"7962","key":"352_CR154","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-023-06061-0","volume":"617","author":"H Yuan","year":"2023","unstructured":"Yuan H, Wu X, Wu Q, Chatoff A, Megill E, Gao J, et al. Lysine catabolism reprograms tumour immunity through histone crotonylation. Nature. 2023;617(7962):818\u201326. https:\/\/doi.org\/10.1038\/s41586-023-06061-0.","journal-title":"Nature"},{"issue":"1","key":"352_CR155","doi-asserted-by":"publisher","first-page":"e000199","DOI":"10.1136\/bmjonc-2023-000199","volume":"2","author":"Z Liu","year":"2023","unstructured":"Liu Z, Jin K, Xu Z, Xu J, Su X, Li B, et al. Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene KDM6A mutation. BMJ Oncol. 2023;2(1):e000199. https:\/\/doi.org\/10.1136\/bmjonc-2023-000199.","journal-title":"BMJ Oncol"},{"issue":"4","key":"352_CR156","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41580-023-00683-y","volume":"25","author":"S Eustermann","year":"2024","unstructured":"Eustermann S, Patel AB, Hopfner KP, He Y, Korber P. Energy-driven genome regulation by ATP-dependent chromatin remodellers. Nat Rev Mol Cell Biol. 2024;25(4):309\u201332. https:\/\/doi.org\/10.1038\/s41580-023-00683-y.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6552","key":"352_CR157","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1126\/science.abf8705","volume":"373","author":"N Mashtalir","year":"2021","unstructured":"Mashtalir N, Dao HT, Sankar A, Liu H, Corin AJ, Bagert JD, et al. Chromatin landscape signals differentially dictate the activities of mSWI\/SNF family complexes. Science. 2021;373(6552):306\u201315. https:\/\/doi.org\/10.1126\/science.abf8705.","journal-title":"Science"},{"issue":"8","key":"352_CR158","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","volume":"41","author":"FJ de Miguel","year":"2023","unstructured":"de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, et al. Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. 2023;41(8):1516-34 e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.005.","journal-title":"Cancer Cell"},{"issue":"1","key":"352_CR159","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41419-025-07711-z","volume":"16","author":"B Dayanc","year":"2025","unstructured":"Dayanc B, Eris S, Gulfirat NE, Ozden-Yilmaz G, Cakiroglu E, Coskun Deniz OS, et al. Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer. Cell Death Dis. 2025;16(1):414. https:\/\/doi.org\/10.1038\/s41419-025-07711-z.","journal-title":"Cell Death Dis"},{"issue":"20","key":"352_CR160","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1158\/1078-0432.CCR-25-0816","volume":"31","author":"Z Liu","year":"2025","unstructured":"Liu Z, Zhang L, Jin K, Zeng H, Su X, Ding Y, et al. ARID1A loss plus CD8+ T-cell infiltration associate with favorable clinical outcomes in urothelial carcinoma. Clin Cancer Res. 2025;31(20):4311\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0816.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"352_CR161","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-012414-040445","volume":"10","author":"J Masliah-Planchon","year":"2015","unstructured":"Masliah-Planchon J, Bieche I, Guinebretiere JM, Bourdeaut F, Delattre O. SWI\/SNF chromatin remodeling and human malignancies. Annu Rev Pathol. 2015;10(1):145. https:\/\/doi.org\/10.1146\/annurev-pathol-012414-040445.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"352_CR162","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","volume":"179","author":"FJ Slack","year":"2019","unstructured":"Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179(5):1033\u201355. https:\/\/doi.org\/10.1016\/j.cell.2019.10.017.","journal-title":"Cell"},{"issue":"3","key":"352_CR163","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2016.117","volume":"16","author":"M Matsui","year":"2017","unstructured":"Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16(3):167\u201379. https:\/\/doi.org\/10.1038\/nrd.2016.117.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"352_CR164","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. M(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37(3):270\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.004.","journal-title":"Cancer Cell"},{"issue":"1","key":"352_CR165","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12943-024-02088-7","volume":"23","author":"H Wang","year":"2024","unstructured":"Wang H, Fleishman JS, Cheng S, Wang W, Wu F, Wang Y, et al. Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance. Mol Cancer. 2024;23(1):177. https:\/\/doi.org\/10.1186\/s12943-024-02088-7.","journal-title":"Mol Cancer"},{"issue":"1","key":"352_CR166","doi-asserted-by":"publisher","first-page":"89","DOI":"10.7150\/ijbs.74227","volume":"19","author":"X Han","year":"2023","unstructured":"Han X, Li M, Xu J, Fu J, Wang X, Wang J, et al. MiR-1275 targets MDK\/AKT signaling to inhibit breast cancer chemoresistance by lessening the properties of cancer stem cells. Int J Biol Sci. 2023;19(1):89\u2013103. https:\/\/doi.org\/10.7150\/ijbs.74227.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"352_CR167","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ccell.2016.03.004","volume":"29","author":"L Qu","year":"2016","unstructured":"Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653\u201368. https:\/\/doi.org\/10.1016\/j.ccell.2016.03.004.","journal-title":"Cancer Cell"},{"issue":"1","key":"352_CR168","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12943-024-02192-8","volume":"23","author":"Y Hu","year":"2024","unstructured":"Hu Y, Cai ZR, Huang RZ, Wang DS, Ju HQ, Chen DL. Circular RNA circPHLPP2 promotes tumor growth and anti-PD-1 resistance through binding ILF3 to regulate IL36gamma transcription in colorectal cancer. Mol Cancer. 2024;23(1):272. https:\/\/doi.org\/10.1186\/s12943-024-02192-8.","journal-title":"Mol Cancer"},{"issue":"10","key":"352_CR169","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41419-022-05317-3","volume":"13","author":"B Ou","year":"2022","unstructured":"Ou B, Liu Y, Gao Z, Xu J, Yan Y, Li Y, et al. Senescent neutrophils-derived exosomal piRNA-17560 promotes chemoresistance and EMT of breast cancer via FTO-mediated m6A demethylation. Cell Death Dis. 2022;13(10):905. https:\/\/doi.org\/10.1038\/s41419-022-05317-3.","journal-title":"Cell Death Dis"},{"issue":"1","key":"352_CR170","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-019-0940-3","volume":"18","author":"L Tan","year":"2019","unstructured":"Tan L, Mai D, Zhang B, Jiang X, Zhang J, Bai R, et al. PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer. 2019;18(1):9. https:\/\/doi.org\/10.1186\/s12943-019-0940-3.","journal-title":"Mol Cancer"},{"issue":"8","key":"352_CR171","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/ijc.35041","volume":"155","author":"J Lu","year":"2024","unstructured":"Lu J, Zhu P, Zhang X, Zeng L, Xu B, Zhou P. tRNA-derived fragments: unveiling new roles and molecular mechanisms in cancer progression. Int J Cancer. 2024;155(8):1347\u201360. https:\/\/doi.org\/10.1002\/ijc.35041.","journal-title":"Int J Cancer"},{"issue":"2","key":"352_CR172","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41576-023-00645-2","volume":"25","author":"S Delaunay","year":"2024","unstructured":"Delaunay S, Helm M, Frye M. RNA modifications in physiology and disease: towards clinical applications. Nat Rev Genet. 2024;25(2):104\u201322. https:\/\/doi.org\/10.1038\/s41576-023-00645-2.","journal-title":"Nat Rev Genet"},{"issue":"7","key":"352_CR173","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187\u2013200. https:\/\/doi.org\/10.1016\/j.cell.2017.05.045.","journal-title":"Cell"},{"issue":"6","key":"352_CR174","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","volume":"20","author":"I Barbieri","year":"2020","unstructured":"Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303\u201322. https:\/\/doi.org\/10.1038\/s41568-020-0253-2.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"352_CR175","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12943-024-02089-6","volume":"23","author":"D Chen","year":"2024","unstructured":"Chen D, Gu X, Nurzat Y, Xu L, Li X, Wu L, et al. Writers, readers, and erasers RNA modifications and drug resistance in cancer. Mol Cancer. 2024;23(1):178. https:\/\/doi.org\/10.1186\/s12943-024-02089-6.","journal-title":"Mol Cancer"},{"issue":"1","key":"352_CR176","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-020-01171-z","volume":"19","author":"X Zhang","year":"2020","unstructured":"Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19(1):47. https:\/\/doi.org\/10.1186\/s12943-020-01171-z.","journal-title":"Mol Cancer"},{"issue":"1","key":"352_CR177","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Yu B, Tao D, Xu X, Xu Y, Wang J, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22(1):91. https:\/\/doi.org\/10.1186\/s12943-023-01782-2.","journal-title":"Mol Cancer"},{"issue":"6","key":"352_CR178","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.62347\/LXOS2662","volume":"14","author":"H Xue","year":"2024","unstructured":"Xue H, Ma Y, Guan K, Zhou Y, Liu Y, Cao F, et al. The role of m6A methylation in targeted therapy resistance in lung cancer. Am J Cancer Res. 2024;14(6):2994\u20133009. https:\/\/doi.org\/10.62347\/LXOS2662.","journal-title":"Am J Cancer Res"},{"key":"352_CR179","doi-asserted-by":"publisher","first-page":"216122","DOI":"10.1016\/j.canlet.2023.216122","volume":"559","author":"L Wang","year":"2023","unstructured":"Wang L, Yang Q, Zhou Q, Fang F, Lei K, Liu Z, et al. METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 2023;559:216122. https:\/\/doi.org\/10.1016\/j.canlet.2023.216122.","journal-title":"Cancer Lett"},{"issue":"1","key":"352_CR180","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-021-01447-y","volume":"21","author":"W Wan","year":"2022","unstructured":"Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, et al. METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022;21(1):60. https:\/\/doi.org\/10.1186\/s12943-021-01447-y.","journal-title":"Mol Cancer"},{"issue":"1","key":"352_CR181","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-021-02088-1","volume":"40","author":"S Nie","year":"2021","unstructured":"Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J, et al. ALKBH5-HOXA10 loop-mediated JAK2 m6a demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021;40(1):284. https:\/\/doi.org\/10.1186\/s13046-021-02088-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"352_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00977-4","author":"EW Tao","year":"2025","unstructured":"Tao EW, Wang Y, Tan J, Chen Y, Sun TY, Hao Y, et al. TRMT6-mediated tRNA m(1)a modification acts as a translational checkpoint of histone synthesis and facilitates colorectal cancer progression. Nat Cancer. 2025. https:\/\/doi.org\/10.1038\/s43018-025-00977-4.","journal-title":"Nat Cancer"},{"issue":"1","key":"352_CR183","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12964-023-01401-z","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang S, Gao X, Ru Y, Gu X, Hu X. Research progress of N1-methyladenosine RNA modification in cancer. Cell Commun Signal. 2024;22(1):79. https:\/\/doi.org\/10.1186\/s12964-023-01401-z.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"352_CR184","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","volume":"83","author":"M Huang","year":"2023","unstructured":"Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res. 2023;83(1):89\u2013102. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0963.","journal-title":"Cancer Res"},{"issue":"3","key":"352_CR185","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cac2.12273","volume":"42","author":"J Chen","year":"2022","unstructured":"Chen J, Li K, Chen J, Wang X, Ling R, Cheng M, et al. Aberrant translation regulated by METTL1\/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression. Cancer Commun. 2022;42(3):223\u201344. https:\/\/doi.org\/10.1002\/cac2.12273.","journal-title":"Cancer Commun"},{"issue":"11","key":"352_CR186","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller JH. Targeting transcription factors in cancer \u2014 from undruggable to reality. Nat Rev Cancer. 2019;19(11):611\u201324. https:\/\/doi.org\/10.1038\/s41568-019-0196-7.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"352_CR187","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1002\/1878-0261.13319","volume":"16","author":"G Donati","year":"2022","unstructured":"Donati G, Amati B. MYC and therapy resistance in cancer: risks and opportunities. Mol Oncol. 2022;16(21):3828\u201354. https:\/\/doi.org\/10.1002\/1878-0261.13319.","journal-title":"Mol Oncol"},{"key":"352_CR188","doi-asserted-by":"publisher","first-page":"1598868","DOI":"10.3389\/fonc.2025.1598868","volume":"15","author":"XQ Tan","year":"2025","unstructured":"Tan XQ, Guo AY, Zheng LF, Xiong J. Research progress on FOXM1 in ovarian cancer diagnosis and therapeutics. Front Oncol. 2025;15:1598868. https:\/\/doi.org\/10.3389\/fonc.2025.1598868.","journal-title":"Front Oncol"},{"issue":"1","key":"352_CR189","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","volume":"11","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xing C, Deng Y, Ye C, Peng H. HIF-1alpha signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2024;11(1):234\u201351. https:\/\/doi.org\/10.1016\/j.gendis.2023.02.039.","journal-title":"Genes Dis"},{"issue":"4","key":"352_CR190","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","volume":"26","author":"KM Lee","year":"2017","unstructured":"Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, et al. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab. 2017;26(4):633-47 e7. https:\/\/doi.org\/10.1016\/j.cmet.2017.09.009.","journal-title":"Cell Metab"},{"issue":"1","key":"352_CR191","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13046-021-01974-y","volume":"40","author":"GH Li","year":"2021","unstructured":"Li GH, Qu Q, Qi TT, Teng XQ, Zhu HH, Wang JJ, et al. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance. J Exp Clin Cancer Res. 2021;40(1):174. https:\/\/doi.org\/10.1186\/s13046-021-01974-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"352_CR192","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.trecan.2017.03.006","volume":"3","author":"S Sengupta","year":"2017","unstructured":"Sengupta S, George RE. Super-enhancer-driven transcriptional dependencies in cancer. Trends Cancer. 2017;3(4):269\u201381. https:\/\/doi.org\/10.1016\/j.trecan.2017.03.006.","journal-title":"Trends Cancer"},{"issue":"1","key":"352_CR193","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12943-025-02295-w","volume":"24","author":"B Lu","year":"2025","unstructured":"Lu B, Chen S, Guan X, Chen X, Du Y, Yuan J, et al. Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer. Mol Cancer. 2025;24(1):83. https:\/\/doi.org\/10.1186\/s12943-025-02295-w.","journal-title":"Mol Cancer"},{"issue":"4","key":"352_CR194","doi-asserted-by":"publisher","first-page":"194977","DOI":"10.1016\/j.bbagrm.2023.194977","volume":"1866","author":"B Bi","year":"2023","unstructured":"Bi B, Qiu M, Liu P, Wang Q, Wen Y, Li Y, et al. Protein post-translational modifications: a key factor in colorectal cancer resistance mechanisms. Biochimica et Biophysica Acta (BBA). 2023;1866(4):194977. https:\/\/doi.org\/10.1016\/j.bbagrm.2023.194977.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"352_CR195","doi-asserted-by":"publisher","first-page":"101173","DOI":"10.1016\/j.drup.2024.101173","volume":"78","author":"C Miao","year":"2025","unstructured":"Miao C, Huang Y, Zhang C, Wang X, Wang B, Zhou X, et al. Post-translational modifications in drug resistance. Drug Resist Updat. 2025;78:101173. https:\/\/doi.org\/10.1016\/j.drup.2024.101173.","journal-title":"Drug Resist Updat"},{"issue":"5","key":"352_CR196","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.62347\/WYKZ9784","volume":"14","author":"L Yu","year":"2024","unstructured":"Yu L, Chen Z, Wu Y, Xu M, Zhong D, Xu H, et al. Unraveling role of ubiquitination in drug resistance of gynecological cancer. Am J Cancer Res. 2024;14(5):2523\u201337. https:\/\/doi.org\/10.62347\/WYKZ9784.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"352_CR197","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41419-022-04599-x","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Li Y, Mao R, Zhang Y, Wen J, Liu Q, et al. DNAJB8 in small extracellular vesicles promotes Oxaliplatin resistance through TP53\/MDR1 pathway in colon cancer. Cell Death Dis. 2022;13(2):151. https:\/\/doi.org\/10.1038\/s41419-022-04599-x.","journal-title":"Cell Death Dis"},{"issue":"14","key":"352_CR198","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2174\/1389450116666141205145620","volume":"15","author":"L Porcelli","year":"2014","unstructured":"Porcelli L, Giovannetti E, Assaraf YG, Jansen G, Scheffer GL, Kathman I, et al. The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib. Curr Drug Targets. 2014;15(14):1322\u201330. https:\/\/doi.org\/10.2174\/1389450116666141205145620.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"352_CR199","doi-asserted-by":"publisher","first-page":"e0708","DOI":"10.1097\/HS9.0000000000000708","volume":"6","author":"M Rehberger","year":"2022","unstructured":"Rehberger M, Schafer JA, Krampitz AM, Bretz AC, Jost L, Haferlach T, et al. The nuclear proteins TP73 and CUL4A confer resistance to cytarabine by induction of translesion DNA synthesis via mono-ubiquitination of PCNA. Hemasphere. 2022;6(5):e0708. https:\/\/doi.org\/10.1097\/HS9.0000000000000708.","journal-title":"Hemasphere"},{"issue":"1","key":"352_CR200","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41419-025-07647-4","volume":"16","author":"F Han","year":"2025","unstructured":"Han F, Qi G, Li R, Peng J, Yan S, Yuan C, et al. USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer. Cell Death Dis. 2025;16(1):305. https:\/\/doi.org\/10.1038\/s41419-025-07647-4.","journal-title":"Cell Death Dis"},{"issue":"1","key":"352_CR201","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41467-022-29401-6","volume":"13","author":"W Xiong","year":"2022","unstructured":"Xiong W, Gao X, Zhang T, Jiang B, Hu MM, Bu X, et al. Usp8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13(1):1700. https:\/\/doi.org\/10.1038\/s41467-022-29401-6.","journal-title":"Nat Commun"},{"issue":"5","key":"352_CR202","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41419-022-04909-3","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Zheng J, Xiao J, Yue J, Shi Z, Xuan Z, et al. TOPK\/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC. Cell Death Dis. 2022;13(5):450. https:\/\/doi.org\/10.1038\/s41419-022-04909-3.","journal-title":"Cell Death Dis"},{"issue":"44","key":"352_CR203","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1038\/s41388-022-02485-6","volume":"41","author":"Y Guo","year":"2022","unstructured":"Guo Y, He J, Zhang H, Chen R, Li L, Liu X, et al. Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression. Oncogene. 2022;41(44):4877\u201392. https:\/\/doi.org\/10.1038\/s41388-022-02485-6.","journal-title":"Oncogene"},{"issue":"12","key":"352_CR204","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.7150\/ijbs.98907","volume":"20","author":"Z Xuan","year":"2024","unstructured":"Xuan Z, Chen C, Sun H, Yang K, Li J, Fu M, et al. NDR1\/FBXO11 promotes phosphorylation-mediated ubiquitination of beta-catenin to suppress metastasis in prostate cancer. Int J Biol Sci. 2024;20(12):4957\u201377. https:\/\/doi.org\/10.7150\/ijbs.98907.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"352_CR205","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12(11):4935\u201348. https:\/\/doi.org\/10.7150\/thno.73223.","journal-title":"Theranostics"},{"key":"352_CR206","doi-asserted-by":"publisher","first-page":"960263","DOI":"10.3389\/fgene.2022.960263","volume":"13","author":"E Contreras-Sanzon","year":"2022","unstructured":"Contreras-Sanzon E, Prado-Garcia H, Romero-Garcia S, Nunez-Corona D, Ortiz-Quintero B, Luna-Rivero C, et al. Histone deacetylases modulate resistance to the therapy in lung cancer. Front Genet. 2022;13:960263. https:\/\/doi.org\/10.3389\/fgene.2022.960263.","journal-title":"Front Genet"},{"key":"352_CR207","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jare.2024.04.032","volume":"70","author":"Z Wei","year":"2025","unstructured":"Wei Z, Ye Y, Liu C, Wang Q, Zhang Y, Chen K, et al. MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma. J Adv Res. 2025;70:287\u2013305. https:\/\/doi.org\/10.1016\/j.jare.2024.04.032.","journal-title":"J Adv Res"},{"key":"352_CR208","doi-asserted-by":"publisher","first-page":"101248","DOI":"10.1016\/j.drup.2025.101248","volume":"81","author":"Y Sun","year":"2025","unstructured":"Sun Y, Wang H, Cui Z, Yu T, Song Y, Gao H, et al. Lactylation in cancer progression and drug resistance. Drug Resist Updat. 2025;81:101248. https:\/\/doi.org\/10.1016\/j.drup.2025.101248.","journal-title":"Drug Resist Updat"},{"key":"352_CR209","doi-asserted-by":"publisher","first-page":"101059","DOI":"10.1016\/j.drup.2024.101059","volume":"73","author":"F Li","year":"2024","unstructured":"Li F, Zhang H, Huang Y, Li D, Zheng Z, Xie K, et al. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist Updat. 2024;73:101059. https:\/\/doi.org\/10.1016\/j.drup.2024.101059.","journal-title":"Drug Resist Updat"},{"issue":"19","key":"352_CR210","doi-asserted-by":"publisher","first-page":"e2309290","DOI":"10.1002\/advs.202309290","volume":"11","author":"Q Yue","year":"2024","unstructured":"Yue Q, Wang Z, Shen Y, Lan Y, Zhong X, Luo X, et al. Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2-mediated MLH1 intron retention. Adv Sci. 2024;11(19):e2309290. https:\/\/doi.org\/10.1002\/advs.202309290.","journal-title":"Adv Sci"},{"issue":"8","key":"352_CR211","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.cmet.2024.07.011","volume":"36","author":"G Li","year":"2024","unstructured":"Li G, Wang D, Zhai Y, Pan C, Zhang J, Wang C, et al. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab. 2024;36(8):1696-710 e10. https:\/\/doi.org\/10.1016\/j.cmet.2024.07.011.","journal-title":"Cell Metab"},{"issue":"4","key":"352_CR212","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1152\/physrev.00025.2019","volume":"100","author":"HM Chang","year":"2020","unstructured":"Chang HM, Yeh ETH. SUMO: from bench to bedside. Physiol Rev. 2020;100(4):1599\u2013619. https:\/\/doi.org\/10.1152\/physrev.00025.2019.","journal-title":"Physiol Rev"},{"key":"352_CR213","doi-asserted-by":"publisher","unstructured":"Yuan H, Lu Y, Chan YT, Zhang C, Wang N, Feng Y. The Role of Protein SUMOylation in Human Hepatocellular Carcinoma: A Potential Target of New Drug Discovery and Development. Cancers (Basel). 2021;13(22). https:\/\/doi.org\/10.3390\/cancers13225700.","DOI":"10.3390\/cancers13225700"},{"issue":"6","key":"352_CR214","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/biof.1984","volume":"49","author":"D Feng","year":"2023","unstructured":"Feng D, He J, Yuan M, Chen Q, Zeng X, Zhou Q, et al. SUMO2\/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307. BioFactors. 2023;49(6):1158\u201373. https:\/\/doi.org\/10.1002\/biof.1984.","journal-title":"BioFactors"},{"issue":"1","key":"352_CR215","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s11658-024-00624-3","volume":"29","author":"B Wei","year":"2024","unstructured":"Wei B, Yang F, Yu L, Qiu C. Crosstalk between SUMOylation and other post-translational modifications in breast cancer. Cell Mol Biol Lett. 2024;29(1):107. https:\/\/doi.org\/10.1186\/s11658-024-00624-3.","journal-title":"Cell Mol Biol Lett"},{"issue":"6","key":"352_CR216","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12032-025-02754-w","volume":"42","author":"SSS Garemilla","year":"2025","unstructured":"Garemilla SSS, Gampa SC, Garimella S. Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance. Med Oncol. 2025;42(6):202. https:\/\/doi.org\/10.1007\/s12032-025-02754-w.","journal-title":"Med Oncol"},{"key":"352_CR217","doi-asserted-by":"publisher","first-page":"874589","DOI":"10.3389\/fimmu.2022.874589","volume":"13","author":"Y Pu","year":"2022","unstructured":"Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression. Front Immunol. 2022;13:874589. https:\/\/doi.org\/10.3389\/fimmu.2022.874589.","journal-title":"Front Immunol"},{"issue":"1","key":"352_CR218","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61. https:\/\/doi.org\/10.1186\/s13045-022-01282-8.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"352_CR219","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13046-022-02524-w","volume":"41","author":"S Rizzolio","year":"2022","unstructured":"Rizzolio S, Giordano S, Corso S. The importance of being CAFs (in cancer resistance to targeted therapies). J Exp Clin Cancer Res. 2022;41(1):319. https:\/\/doi.org\/10.1186\/s13046-022-02524-w.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"352_CR220","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23(1):92. https:\/\/doi.org\/10.1186\/s12943-024-01990-4.","journal-title":"Mol Cancer"},{"issue":"10","key":"352_CR221","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1172\/JCI137552","volume":"130","author":"EC de Heer","year":"2020","unstructured":"de Heer EC, Jalving M, Harris AL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest. 2020;130(10):5074\u201387. https:\/\/doi.org\/10.1172\/JCI137552.","journal-title":"J Clin Invest"},{"key":"352_CR222","doi-asserted-by":"publisher","unstructured":"Bao MH, Wong CC. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells. 2021;10(7). https:\/\/doi.org\/10.3390\/cells10071715.","DOI":"10.3390\/cells10071715"},{"issue":"6","key":"352_CR223","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"key":"352_CR224","doi-asserted-by":"publisher","unstructured":"Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, et al. Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight. 2017;2(23). https:\/\/doi.org\/10.1172\/jci.insight.95128.","DOI":"10.1172\/jci.insight.95128"},{"issue":"20","key":"352_CR225","first-page":"5638","volume":"49","author":"O Alabaster","year":"1989","unstructured":"Alabaster O, Woods T, Ortiz-Sanchez V, Jahangeer S. Influence of microenvironmental pH on adriamycin resistance. Cancer Res. 1989;49(20):5638\u201343.","journal-title":"Cancer Res"},{"key":"352_CR226","doi-asserted-by":"publisher","first-page":"101149","DOI":"10.1016\/j.drup.2024.101149","volume":"77","author":"C Qiu","year":"2024","unstructured":"Qiu C, Tang C, Tang Y, Su K, Chai X, Zhan Z, et al. RGS5+ lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism. Drug Resist Updat. 2024;77:101149. https:\/\/doi.org\/10.1016\/j.drup.2024.101149.","journal-title":"Drug Resist Updat"},{"key":"352_CR227","doi-asserted-by":"publisher","unstructured":"Ji S, Wu W, Jiang Q. Crosstalk between Endothelial Cells and Tumor Cells: A New Era in Prostate Cancer Progression. Int J Mol Sci. 2023;24(23). https:\/\/doi.org\/10.3390\/ijms242316893.","DOI":"10.3390\/ijms242316893"},{"issue":"4","key":"352_CR228","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","volume":"82","author":"Y Lu","year":"2025","unstructured":"Lu Y, Liu Y, Zuo X, Li G, Wang J, Liu J, et al. CXCL12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma. J Hepatol. 2025;82(4):634\u201348. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.044.","journal-title":"J Hepatol"},{"issue":"1","key":"352_CR229","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, et al. TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79(1):126\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.032.","journal-title":"J Hepatol"},{"issue":"5","key":"352_CR230","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai Z, Lin Y, Lin P, Zhao X, Cui L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 2024;15(5):307. https:\/\/doi.org\/10.1038\/s41419-024-06697-4.","journal-title":"Cell Death Dis"},{"issue":"728","key":"352_CR231","doi-asserted-by":"publisher","first-page":"eadg3840","DOI":"10.1126\/scitranslmed.adg3840","volume":"16","author":"JJF Sleeboom","year":"2024","unstructured":"Sleeboom JJF, van Tienderen GS, Schenke-Layland K, van der Laan LJW, Khalil AA, Verstegen MMA. The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets. Sci Transl Med. 2024;16(728):eadg3840. https:\/\/doi.org\/10.1126\/scitranslmed.adg3840.","journal-title":"Sci Transl Med"},{"issue":"9","key":"352_CR232","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41416-021-01680-8","volume":"126","author":"B Darvishi","year":"2022","unstructured":"Darvishi B, Eisavand MR, Majidzadeh AK, Farahmand L. Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance. Br J Cancer. 2022;126(9):1253\u201363. https:\/\/doi.org\/10.1038\/s41416-021-01680-8.","journal-title":"Br J Cancer"},{"issue":"11","key":"352_CR233","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1158\/0008-5472.CAN-07-6390","volume":"68","author":"CC Park","year":"2008","unstructured":"Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008;68(11):4398\u2013405. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6390.","journal-title":"Cancer Res"},{"issue":"5","key":"352_CR234","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.stem.2017.10.001","volume":"21","author":"JA Brown","year":"2017","unstructured":"Brown JA, Yonekubo Y, Hanson N, Sastre-Perona A, Basin A, Rytlewski JA, et al. TGF-beta-Induced Quiescence Mediates Chemoresistance of Tumor-Propagating Cells in Squamous Cell Carcinoma. Cell Stem Cell. 2017;21(5):650-64 e8. https:\/\/doi.org\/10.1016\/j.stem.2017.10.001.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"352_CR235","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.7150\/thno.50613","volume":"11","author":"C Zhong","year":"2021","unstructured":"Zhong C, Tao B, Tang F, Yang X, Peng T, You J, et al. Remodeling cancer stemness by collagen\/fibronectin via the AKT and CDC42 signaling pathway crosstalk in glioma. Theranostics. 2021;11(4):1991\u20132005. https:\/\/doi.org\/10.7150\/thno.50613.","journal-title":"Theranostics"},{"issue":"38","key":"352_CR236","doi-asserted-by":"publisher","first-page":"26038","DOI":"10.1074\/jbc.M114.564120","volume":"289","author":"T Chanmee","year":"2014","unstructured":"Chanmee T, Ontong P, Mochizuki N, Kongtawelert P, Konno K, Itano N. Excessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of Twist and the transforming growth factor beta (TGF-beta)-Snail signaling axis. J Biol Chem. 2014;289(38):26038\u201356. https:\/\/doi.org\/10.1074\/jbc.M114.564120.","journal-title":"J Biol Chem"},{"issue":"22","key":"352_CR237","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1091\/mbc.E15-07-0456","volume":"26","author":"CH Lin","year":"2015","unstructured":"Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, et al. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Mol Biol Cell. 2015;26(22):3946\u201353. https:\/\/doi.org\/10.1091\/mbc.E15-07-0456.","journal-title":"Mol Biol Cell"},{"issue":"11","key":"352_CR238","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41418-019-0310-0","volume":"26","author":"JE Long","year":"2019","unstructured":"Long JE, Wongchenko MJ, Nickles D, Chung WJ, Wang BE, Riegler J, et al. Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation. Cell Death Differ. 2019;26(11):2416\u201329. https:\/\/doi.org\/10.1038\/s41418-019-0310-0.","journal-title":"Cell Death Differ"},{"key":"352_CR239","doi-asserted-by":"publisher","unstructured":"Deng M, Lin J, Nowsheen S, Liu T, Zhao Y, Villalta PW, et al. Extracellular matrix stiffness determines DNA repair efficiency and cellular sensitivity to genotoxic agents. Sci Adv. 2020;6(37). https:\/\/doi.org\/10.1126\/sciadv.abb2630.","DOI":"10.1126\/sciadv.abb2630"},{"key":"352_CR240","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.arr.2016.11.005","volume":"35","author":"JF Moreau","year":"2017","unstructured":"Moreau JF, Pradeu T, Grignolio A, Nardini C, Castiglione F, Tieri P, et al. The emerging role of ECM crosslinking in T cell mobility as a hallmark of immunosenescence in humans. Ageing Res Rev. 2017;35:322. https:\/\/doi.org\/10.1016\/j.arr.2016.11.005.","journal-title":"Ageing Res Rev"},{"key":"352_CR241","doi-asserted-by":"publisher","unstructured":"Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. 2021;10. https:\/\/doi.org\/10.7554\/eLife.58688.","DOI":"10.7554\/eLife.58688"},{"key":"352_CR242","doi-asserted-by":"publisher","first-page":"114319","DOI":"10.1016\/j.addr.2022.114319","volume":"186","author":"T Zhang","year":"2022","unstructured":"Zhang T, Jia Y, Yu Y, Zhang B, Xu F, Guo H. Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy. Adv Drug Deliv Rev. 2022;186:114319. https:\/\/doi.org\/10.1016\/j.addr.2022.114319.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"352_CR243","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.bbrc.2017.12.115","volume":"495","author":"A Miyazawa","year":"2018","unstructured":"Miyazawa A, Ito S, Asano S, Tanaka I, Sato M, Kondo M, et al. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem Biophys Res Commun. 2018;495(3):2344\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2017.12.115.","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"352_CR244","doi-asserted-by":"publisher","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","volume":"65","author":"MS Eno","year":"2022","unstructured":"Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, et al. Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer. J Med Chem. 2022;65(14):9662\u201377. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00704.","journal-title":"J Med Chem"},{"key":"352_CR245","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S. Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56\u201363. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"352_CR246","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7(9):1929\u201343. https:\/\/doi.org\/10.1182\/bloodadvances.2022008447.","journal-title":"Blood Adv"},{"issue":"1","key":"352_CR247","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11(1):3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2.","journal-title":"Nat Commun"},{"issue":"9","key":"352_CR248","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","volume":"5","author":"V Thatikonda","year":"2024","unstructured":"Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow CA, Albrecht C, et al. Co-targeting SOS1 enhances the antitumor effects of KRAS(G12C) inhibitors by addressing intrinsic and acquired resistance. Nat Cancer. 2024;5(9):1352\u201370. https:\/\/doi.org\/10.1038\/s43018-024-00800-6.","journal-title":"Nat Cancer"},{"issue":"6","key":"352_CR249","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3324\/haematol.2022.281538","volume":"108","author":"L Li","year":"2023","unstructured":"Li L, Nie L, Jordan A, Cai Q, Liu Y, Li Y, et al. Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2023;108(6):1616\u201327. https:\/\/doi.org\/10.3324\/haematol.2022.281538.","journal-title":"Haematologica"},{"issue":"6","key":"352_CR250","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41419-020-2646-2","volume":"11","author":"N Mukherjee","year":"2020","unstructured":"Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, et al. MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020;11(6):443. https:\/\/doi.org\/10.1038\/s41419-020-2646-2.","journal-title":"Cell Death Dis"},{"issue":"7","key":"352_CR251","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-017-0608-3","volume":"19","author":"KM Wong","year":"2017","unstructured":"Wong KM, Horton KJ, Coveler AL, Hingorani SR, Harris WP. Targeting the tumor stroma: the biology and clinical development of Pegylated Recombinant Human Hyaluronidase (PEGPH20). Curr Oncol Rep. 2017;19(7):47. https:\/\/doi.org\/10.1007\/s11912-017-0608-3.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"352_CR252","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13046-021-02070-x","volume":"40","author":"L Morosi","year":"2021","unstructured":"Morosi L, Meroni M, Ubezio P, Fuso Nerini I, Minoli L, Porcu L, et al. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. J Exp Clin Cancer Res. 2021;40(1):286. https:\/\/doi.org\/10.1186\/s13046-021-02070-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"352_CR253","doi-asserted-by":"publisher","first-page":"100984","DOI":"10.1016\/j.tranon.2020.100984","volume":"14","author":"F Heil","year":"2021","unstructured":"Heil F, Babitzki G, Julien-Laferriere A, Ooi CH, Hidalgo M, Massard C, et al. Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies. Transl Oncol. 2021;14(2):100984. https:\/\/doi.org\/10.1016\/j.tranon.2020.100984.","journal-title":"Transl Oncol"},{"issue":"11","key":"352_CR254","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/psp4.12142","volume":"5","author":"LG Hutchinson","year":"2016","unstructured":"Hutchinson LG, Mueller HJ, Gaffney EA, Maini PK, Wagg J, Phipps A, et al. Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs. CPT Pharmacometrics Syst Pharmacol. 2016;5(11):636\u201345. https:\/\/doi.org\/10.1002\/psp4.12142.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"352_CR255","doi-asserted-by":"publisher","first-page":"120350","DOI":"10.1016\/j.ijpharm.2021.120350","volume":"598","author":"H Zhang","year":"2021","unstructured":"Zhang H, Almuqbil RM, Alhudaithi SS, Sunbul FS, da Rocha SRP. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model. Int J Pharm. 2021;598:120350. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120350.","journal-title":"Int J Pharm"},{"issue":"9","key":"352_CR256","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/carcin\/bgac043","volume":"43","author":"AN Omstead","year":"2022","unstructured":"Omstead AN, Paskewicz M, Gorbunova A, Zheng P, Salvitti MS, Mansoor R, et al. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model. Carcinogenesis. 2022;43(9):842\u201350. https:\/\/doi.org\/10.1093\/carcin\/bgac043.","journal-title":"Carcinogenesis"},{"issue":"7","key":"352_CR257","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41591-025-03776-7","volume":"31","author":"SY Wu","year":"2025","unstructured":"Wu SY, Jin X, Liu Y, Wang ZY, Zuo WJ, Ma D, et al. Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nat Med. 2025;31(7):2405\u201315. https:\/\/doi.org\/10.1038\/s41591-025-03776-7.","journal-title":"Nat Med"},{"issue":"1","key":"352_CR258","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s11671-022-03668-6","volume":"17","author":"Z Liu","year":"2022","unstructured":"Liu Z, Ji X, He D, Zhang R, Liu Q, Xin T. Nanoscale drug delivery systems in glioblastoma. Nanoscale Res Lett. 2022;17(1):27. https:\/\/doi.org\/10.1186\/s11671-022-03668-6.","journal-title":"Nanoscale Res Lett"},{"issue":"29","key":"352_CR259","doi-asserted-by":"publisher","first-page":"e2400502","DOI":"10.1002\/adma.202400502","volume":"36","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ma H, Li L, Sun C, Yu C, Wang L, et al. Dual-Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy. Adv Mater. 2024;36(29):e2400502. https:\/\/doi.org\/10.1002\/adma.202400502.","journal-title":"Adv Mater"},{"issue":"1","key":"352_CR260","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12951-022-01360-6","volume":"20","author":"B Liu","year":"2022","unstructured":"Liu B, Ji Q, Cheng Y, Liu M, Zhang B, Mei Q, et al. Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM. J Nanobiotechnology. 2022;20(1):161. https:\/\/doi.org\/10.1186\/s12951-022-01360-6.","journal-title":"J Nanobiotechnology"},{"issue":"5","key":"352_CR261","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1021\/acsnano.3c07002","volume":"18","author":"C Qu","year":"2024","unstructured":"Qu C, Yuan H, Tian M, Zhang X, Xia P, Shi G, et al. Precise photodynamic therapy by Midkine nanobody-engineered nanoparticles remodels the microenvironment of pancreatic ductal adenocarcinoma and potentiates the immunotherapy. ACS Nano. 2024;18(5):4019\u201337. https:\/\/doi.org\/10.1021\/acsnano.3c07002.","journal-title":"ACS Nano"},{"key":"352_CR262","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.actbio.2022.02.006","volume":"142","author":"G Zhang","year":"2022","unstructured":"Zhang G, Li N, Qi Y, Zhao Q, Zhan J, Yu D. Synergistic ferroptosis-gemcitabine chemotherapy of the gemcitabine loaded carbonaceous nanozymes to enhance the treatment and magnetic resonance imaging monitoring of pancreatic cancer. Acta Biomater. 2022;142:284. https:\/\/doi.org\/10.1016\/j.actbio.2022.02.006.","journal-title":"Acta Biomater"},{"issue":"1","key":"352_CR263","doi-asserted-by":"publisher","first-page":"vdae041","DOI":"10.1093\/noajnl\/vdae041","volume":"6","author":"JJ Jones","year":"2024","unstructured":"Jones JJ, Jones KL, Wong SQ, Whittle J, Goode D, Nguyen H, et al. Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma. Neuro-Oncol Adv. 2024;6(1):vdae041. https:\/\/doi.org\/10.1093\/noajnl\/vdae041.","journal-title":"Neuro-Oncol Adv"},{"issue":"24","key":"352_CR264","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.21.02615","volume":"40","author":"M Malla","year":"2022","unstructured":"Malla M, Loree JM, Kasi PM, Parikh AR. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2846\u201357. https:\/\/doi.org\/10.1200\/JCO.21.02615.","journal-title":"J Clin Oncol"},{"issue":"1","key":"352_CR265","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13046-020-01549-3","volume":"39","author":"MT Di Martino","year":"2020","unstructured":"Di Martino MT, Meschini S, Scotlandi K, Riganti C, De Smaele E, Zazzeroni F, et al. From single gene analysis to single cell profiling: a new era for precision medicine. J Exp Clin Cancer Res. 2020;39(1):48. https:\/\/doi.org\/10.1186\/s13046-020-01549-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"352_CR266","doi-asserted-by":"publisher","first-page":"2816 e13","DOI":"10.1016\/j.immuni.2023.11.008","volume":"56","author":"O Dufva","year":"2023","unstructured":"Dufva O, Gandolfi S, Huuhtanen J, Dashevsky O, Duan H, Saeed K, et al. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity. 2023;56(12):2816 e13-2835. https:\/\/doi.org\/10.1016\/j.immuni.2023.11.008.","journal-title":"Immunity"},{"issue":"18","key":"352_CR267","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1158\/0008-5472.CAN-20-2811","volume":"81","author":"Y Kashima","year":"2021","unstructured":"Kashima Y, Shibahara D, Suzuki A, Muto K, Kobayashi IS, Plotnick D, et al. Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Cancer Res. 2021;81(18):4835\u201348. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2811.","journal-title":"Cancer Res"},{"issue":"1","key":"352_CR268","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-023-01218-y","volume":"15","author":"S Zhang","year":"2023","unstructured":"Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med. 2023;15(1):72. https:\/\/doi.org\/10.1186\/s13073-023-01218-y.","journal-title":"Genome Med"},{"key":"352_CR269","doi-asserted-by":"publisher","first-page":"100811","DOI":"10.1016\/j.drup.2022.100811","volume":"60","author":"B Bueschbell","year":"2022","unstructured":"Bueschbell B, Caniceiro AB, Suzano PMS, Machuqueiro M, Rosario-Ferreira N, Moreira IS. Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. Drug Resist Updat. 2022;60:100811. https:\/\/doi.org\/10.1016\/j.drup.2022.100811.","journal-title":"Drug Resist Updat"},{"issue":"4","key":"352_CR270","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/SLA.0000000000006279","volume":"281","author":"W Li","year":"2025","unstructured":"Li W, Huang YH, Zhu T, Zhang YM, Zheng XX, Zhang TF, et al. Noninvasive Artificial Intelligence System for Early Predicting Residual Cancer Burden During Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2025;281(4):645\u201354. https:\/\/doi.org\/10.1097\/SLA.0000000000006279.","journal-title":"Ann Surg"},{"issue":"1","key":"352_CR271","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","volume":"14","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang ZX, Chen YX, Wu HX, Yin L, Zhao Q, et al. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022;14(1):45. https:\/\/doi.org\/10.1186\/s13073-022-01050-w.","journal-title":"Genome Med"},{"issue":"5","key":"352_CR272","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2589-7500(22)00024-3","volume":"4","author":"S Wang","year":"2022","unstructured":"Wang S, Yu H, Gan Y, Wu Z, Li E, Li X, et al. Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study. Lancet Digit Health. 2022;4(5):e309\u201319. https:\/\/doi.org\/10.1016\/S2589-7500(22)00024-3.","journal-title":"Lancet Digit Health"},{"issue":"1","key":"352_CR273","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41467-021-27833-0","volume":"13","author":"Z Qi","year":"2022","unstructured":"Qi Z, Xu Z, Zhang L, Zou Y, Li J, Yan W, et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kalpha\/beta\/delta treatment. Nat Commun. 2022;13(1):182. https:\/\/doi.org\/10.1038\/s41467-021-27833-0.","journal-title":"Nat Commun"},{"issue":"1","key":"352_CR274","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.euo.2024.08.006","volume":"8","author":"M Ruiz-Vico","year":"2025","unstructured":"Ruiz-Vico M, Wetterskog D, Orlando F, Thakali S, Wingate A, Jayaram A, et al. Liquid biopsy in progressing prostate cancer patients starting docetaxel with or without enzalutamide: a biomarker study of the PRESIDE phase 3b trial. Eur Urol Oncol. 2025;8(1):135\u201344. https:\/\/doi.org\/10.1016\/j.euo.2024.08.006.","journal-title":"Eur Urol Oncol"},{"issue":"6649","key":"352_CR275","doi-asserted-by":"publisher","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science. 2023;380(6649):eabo2296. https:\/\/doi.org\/10.1126\/science.abo2296.","journal-title":"Science"},{"key":"352_CR276","doi-asserted-by":"publisher","first-page":"104834","DOI":"10.1016\/j.ebiom.2023.104834","volume":"97","author":"L Joachim","year":"2023","unstructured":"Joachim L, Gottert S, Sax A, Steiger K, Neuhaus K, Heinrich P, et al. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors. EBioMedicine. 2023;97:104834. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104834.","journal-title":"EBioMedicine"},{"issue":"4","key":"352_CR277","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","volume":"71","author":"J Huang","year":"2022","unstructured":"Huang J, Liu D, Wang Y, Liu L, Li J, Yuan J, et al. Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1\/programmed cell death ligand 1 (anti-PD-1\/PD-L1) immunotherapy. Gut. 2022;71(4):734\u201345. https:\/\/doi.org\/10.1136\/gutjnl-2020-321031.","journal-title":"Gut"},{"issue":"1","key":"352_CR278","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40168-025-02045-6","volume":"13","author":"A Rodriguez-Garcia","year":"2025","unstructured":"Rodriguez-Garcia A, Ancos-Pintado R, Garcia-Vicente R, Ortiz-Ruiz A, Arroyo A, Navarro MA, et al. Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy. Microbiome. 2025;13(1):56. https:\/\/doi.org\/10.1186\/s40168-025-02045-6.","journal-title":"Microbiome"},{"key":"352_CR279","doi-asserted-by":"publisher","first-page":"101222","DOI":"10.1016\/j.drup.2025.101222","volume":"80","author":"H Wu","year":"2025","unstructured":"Wu H, Liu J, Zhang XH, Jin S, Li P, Liu H, et al. The combination of flaxseed lignans and PD-1\/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity. Drug Resist Updat. 2025;80:101222. https:\/\/doi.org\/10.1016\/j.drup.2025.101222.","journal-title":"Drug Resist Updat"},{"key":"352_CR280","doi-asserted-by":"publisher","first-page":"107278","DOI":"10.1016\/j.phrs.2024.107278","volume":"206","author":"Q Xu","year":"2024","unstructured":"Xu Q, Gao J, Zhao R, Li H, Cui H, Yuan Z, et al. Akkermansia muciniphila-derived pentadecanoic acid enhances oxaliplatin sensitivity in gastric cancer by modulating glycolysis. Pharmacol Res. 2024;206:107278. https:\/\/doi.org\/10.1016\/j.phrs.2024.107278.","journal-title":"Pharmacol Res"},{"issue":"1","key":"352_CR281","doi-asserted-by":"publisher","first-page":"10726","DOI":"10.1038\/s41467-024-55388-3","volume":"15","author":"CY Kim","year":"2024","unstructured":"Kim CY, Park DJ, Ahn BC, Baek S, Hong MH, Nguyen LT, et al. A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy. Nat Commun. 2024;15(1):10726. https:\/\/doi.org\/10.1038\/s41467-024-55388-3.","journal-title":"Nat Commun"},{"issue":"7","key":"352_CR282","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.immuni.2024.04.025","volume":"57","author":"J Mannion","year":"2024","unstructured":"Mannion J, Gifford V, Bellenie B, Fernando W, Ramos Garcia L, Wilson R, et al. A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity. 2024;57(7):1514-32 e15. https:\/\/doi.org\/10.1016\/j.immuni.2024.04.025.","journal-title":"Immunity"},{"issue":"1","key":"352_CR283","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41467-023-44237-4","volume":"15","author":"M Schroder","year":"2024","unstructured":"Schroder M, Renatus M, Liang X, Meili F, Zoller T, Ferrand S, et al. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance. Nat Commun. 2024;15(1):275. https:\/\/doi.org\/10.1038\/s41467-023-44237-4.","journal-title":"Nat Commun"},{"issue":"16","key":"352_CR284","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, et al. Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin Cancer Res. 2024;30(16):3549\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"352_CR285","doi-asserted-by":"publisher","first-page":"10683","DOI":"10.1038\/s41467-024-55006-2","volume":"15","author":"X Yu","year":"2024","unstructured":"Yu X, Lu D, Qi X, Paudel RR, Lin H, Holloman BL, et al. Development of a RIPK1 degrader to enhance antitumor immunity. Nat Commun. 2024;15(1):10683. https:\/\/doi.org\/10.1038\/s41467-024-55006-2.","journal-title":"Nat Commun"},{"issue":"1","key":"352_CR286","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13046-024-03237-y","volume":"43","author":"Y Guo","year":"2024","unstructured":"Guo Y, Li Y, Zhou Z, Hou L, Liu W, Ren W, et al. Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer. J Exp Clin Cancer Res. 2024;43(1):314. https:\/\/doi.org\/10.1186\/s13046-024-03237-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"15","key":"352_CR287","doi-asserted-by":"publisher","first-page":"e2309204","DOI":"10.1002\/advs.202309204","volume":"11","author":"LP Zhao","year":"2024","unstructured":"Zhao LP, Zheng RR, Rao XN, Huang CY, Zhou HY, Yu XY, et al. Chemotherapy-Enabled Colorectal Cancer Immunotherapy of Self-Delivery Nano-PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance. Adv Sci (Weinh). 2024;11(15):e2309204. https:\/\/doi.org\/10.1002\/advs.202309204.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"352_CR288","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7150\/thno.99588","volume":"15","author":"X Fu","year":"2025","unstructured":"Fu X, Huang J, Chen X, Xie D, Chen H, Liang Z, et al. Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma. Theranostics. 2025;15(1):103\u201321. https:\/\/doi.org\/10.7150\/thno.99588.","journal-title":"Theranostics"},{"key":"352_CR289","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jconrel.2024.10.007","volume":"376","author":"R Vartak","year":"2024","unstructured":"Vartak R, Patel K. Targeted nanoliposomes of oncogenic protein degraders: significant inhibition of tumor in lung-cancer bearing mice. J Control Release. 2024;376:502. https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.007.","journal-title":"J Control Release"},{"issue":"4","key":"352_CR290","doi-asserted-by":"publisher","first-page":"102053","DOI":"10.1016\/j.xcrm.2025.102053","volume":"6","author":"S Chia","year":"2025","unstructured":"Chia S, Wen Seow JJ, Peras da Silva R, Suphavilai C, Shirgaonkar N, Murata-Hori M, et al. CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Rep Med. 2025;6(4):102053. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102053.","journal-title":"Cell Rep Med."},{"issue":"7","key":"352_CR291","doi-asserted-by":"publisher","first-page":"e2406624","DOI":"10.1002\/advs.202406624","volume":"12","author":"D Chen","year":"2025","unstructured":"Chen D, Liu P, Lin J, Zang L, Liu Y, Zhai S, et al. A Distinguished Roadmap of Fibroblast Senescence in Predicting Immunotherapy Response and Prognosis Across Human Cancers. Adv Sci (Weinh). 2025;12(7):e2406624. https:\/\/doi.org\/10.1002\/advs.202406624.","journal-title":"Adv Sci (Weinh)"},{"key":"352_CR292","doi-asserted-by":"publisher","unstructured":"Fomin V, So WV, Barbieri RA, Hiller-Bittrolff K, Koletou E, Tu T, et al. Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC. J Immunother Cancer. 2025;13(3). https:\/\/doi.org\/10.1136\/jitc-2024-009092.","DOI":"10.1136\/jitc-2024-009092"},{"issue":"11","key":"352_CR293","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","volume":"42","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. J Clin Oncol. 2024;42(11):1311\u201321. https:\/\/doi.org\/10.1200\/JCO.23.00580.","journal-title":"J Clin Oncol"},{"issue":"1","key":"352_CR294","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.1038\/s41467-024-52555-4","volume":"15","author":"S Sahni","year":"2024","unstructured":"Sahni S, Wang B, Wu D, Dhruba SR, Nagy M, Patkar S, et al. A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade. Nat Commun. 2024;15(1):8867. https:\/\/doi.org\/10.1038\/s41467-024-52555-4.","journal-title":"Nat Commun"},{"issue":"12","key":"352_CR295","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","volume":"42","author":"H Hamidi","year":"2024","unstructured":"Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell. 2024;42(12):2098-112 e4. https:\/\/doi.org\/10.1016\/j.ccell.2024.10.016.","journal-title":"Cancer Cell"},{"issue":"1","key":"352_CR296","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13046-024-03111-x","volume":"43","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Liu Z, Gong C, Zhang J, Zhao J, Zhang X, et al. Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy. J Exp Clin Cancer Res. 2024;43(1):232. https:\/\/doi.org\/10.1186\/s13046-024-03111-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"14","key":"352_CR297","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/0008-5472.CAN-24-3840","volume":"85","author":"Y Chen","year":"2025","unstructured":"Chen Y, He L, Ianevski A, Nader K, Ruokoranta T, Linnavirta N, et al. A machine learning-based strategy predicts selective and synergistic drug combinations for relapsed acute myeloid leukemia. Cancer Res. 2025;85(14):2753\u201368. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-3840.","journal-title":"Cancer Res"},{"issue":"11","key":"352_CR298","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.7150\/ijbs.98899","volume":"20","author":"Z Zhuo","year":"2024","unstructured":"Zhuo Z, Wang J, Zhang Y, Meng G. Integrative alternative splicing analysis reveals new prognosis signature in B-cell acute lymphoblastic leukemia. Int J Biol Sci. 2024;20(11):4496\u2013512. https:\/\/doi.org\/10.7150\/ijbs.98899.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"352_CR299","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1038\/s41467-024-52980-5","volume":"15","author":"A Ianevski","year":"2024","unstructured":"Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, et al. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones. Nat Commun. 2024;15(1):8579. https:\/\/doi.org\/10.1038\/s41467-024-52980-5.","journal-title":"Nat Commun"},{"issue":"5","key":"352_CR300","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.7150\/thno.91626","volume":"14","author":"W Sun","year":"2024","unstructured":"Sun W, Zhu Y, Zou Z, Wang L, Zhong J, Shen K, et al. An advanced comprehensive muti-cell-type-specific model for predicting anti-PD-1 therapeutic effect in melanoma. Theranostics. 2024;14(5):2127\u201350. https:\/\/doi.org\/10.7150\/thno.91626.","journal-title":"Theranostics"},{"key":"352_CR301","doi-asserted-by":"publisher","first-page":"217565","DOI":"10.1016\/j.canlet.2025.217565","volume":"616","author":"T Tamura","year":"2025","unstructured":"Tamura T, Nagai S, Masuda K, Imaeda K, Sugihara E, Yamasaki J, et al. mTOR-mediated p62\/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer. Cancer Lett. 2025;616:217565. https:\/\/doi.org\/10.1016\/j.canlet.2025.217565.","journal-title":"Cancer Lett"},{"issue":"1","key":"352_CR302","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-020-01734-4","volume":"39","author":"J Sun","year":"2020","unstructured":"Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q, et al. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 2020;39(1):222. https:\/\/doi.org\/10.1186\/s13046-020-01734-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"352_CR303","doi-asserted-by":"publisher","first-page":"216594","DOI":"10.1016\/j.canlet.2023.216594","volume":"582","author":"W Hong","year":"2024","unstructured":"Hong W, Zhang Y, Wang S, Zheng D, Hsu S, Zhou J, et al. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma. Cancer Lett. 2024;582:216594. https:\/\/doi.org\/10.1016\/j.canlet.2023.216594.","journal-title":"Cancer Lett"},{"issue":"14","key":"352_CR304","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1158\/1078-0432.CCR-23-3608","volume":"30","author":"T Tang","year":"2024","unstructured":"Tang T, Zhou Z, Chen M, Li N, Sun J, Chen Z, et al. Plasma metabolic profiles-based prediction of induction chemotherapy efficacy in nasopharyngeal carcinoma: results of a bidirectional clinical trial. Clin Cancer Res. 2024;30(14):2925\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3608.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"352_CR305","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-23-0641","volume":"14","author":"X Zhao","year":"2024","unstructured":"Zhao X, Singhal A, Park S, Kong J, Bachelder R, Ideker T. Cancer mutations converge on a collection of protein assemblies to predict resistance to replication stress. Cancer Discov. 2024;14(3):508\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0641.","journal-title":"Cancer Discov"},{"issue":"3","key":"352_CR306","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264\u201379. https:\/\/doi.org\/10.3322\/caac.21657.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"352_CR307","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41392-024-01932-y","volume":"9","author":"Z Chen","year":"2024","unstructured":"Chen Z, Chen Y, Sun Y, Tang L, Zhang L, Hu Y, et al. Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data. Signal Transduct Target Ther. 2024;9(1):222. https:\/\/doi.org\/10.1038\/s41392-024-01932-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"352_CR308","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.1038\/s41467-022-34277-7","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Wang X, Ma A, Wang QE, Liu B, Li L, et al. Deep transfer learning of cancer drug responses by integrating bulk and single-cell RNA-seq data. Nat Commun. 2022;13(1):6494. https:\/\/doi.org\/10.1038\/s41467-022-34277-7.","journal-title":"Nat Commun"},{"issue":"6","key":"352_CR309","doi-asserted-by":"publisher","first-page":"101579","DOI":"10.1016\/j.xcrm.2024.101579","volume":"5","author":"X Bi","year":"2024","unstructured":"Bi X, Wang J, Xue B, He C, Liu F, Chen H, et al. Sersomes for metabolic phenotyping and prostate cancer diagnosis. Cell Rep Med. 2024;5(6):101579. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101579.","journal-title":"Cell Rep Med"},{"issue":"14","key":"352_CR310","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748\u201357. https:\/\/doi.org\/10.1200\/JCO.2012.43.1882.","journal-title":"J Clin Oncol"},{"issue":"7880","key":"352_CR311","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-021-03922-4","volume":"598","author":"HA Elmarakeby","year":"2021","unstructured":"Elmarakeby HA, Hwang J, Arafeh R, Crowdis J, Gang S, Liu D, et al. Biologically informed deep neural network for prostate cancer discovery. Nature. 2021;598(7880):348\u201352. https:\/\/doi.org\/10.1038\/s41586-021-03922-4.","journal-title":"Nature"},{"issue":"11","key":"352_CR312","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-23-2040","volume":"84","author":"K Gallagher","year":"2024","unstructured":"Gallagher K, Strobl MAR, Park DS, Spoendlin FC, Gatenby RA, Maini PK, et al. Mathematical model-driven deep learning enables personalized adaptive therapy. Cancer Res. 2024;84(11):1929\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2040.","journal-title":"Cancer Res"},{"issue":"8042","key":"352_CR313","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","volume":"636","author":"GS Sonke","year":"2024","unstructured":"Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature. 2024;636(8042):474\u201380. https:\/\/doi.org\/10.1038\/s41586-024-08035-2.","journal-title":"Nature"},{"issue":"9","key":"352_CR314","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol. 2025;43(9):1101\u201312. https:\/\/doi.org\/10.1200\/JCO-24-02086.","journal-title":"J Clin Oncol"},{"issue":"7","key":"352_CR315","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s43018-024-00740-1","volume":"5","author":"S Park","year":"2024","unstructured":"Park S, Silva E, Singhal A, Kelly MR, Licon K, Panagiotou I, et al. A deep learning model of tumor cell architecture elucidates response and resistance to CDK4\/6 inhibitors. Nat Cancer. 2024;5(7):996\u20131009. https:\/\/doi.org\/10.1038\/s43018-024-00740-1.","journal-title":"Nat Cancer"},{"issue":"2","key":"352_CR316","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101\u201326. https:\/\/doi.org\/10.1038\/s41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"10075","key":"352_CR317","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195\u2013205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2.","journal-title":"Lancet"},{"key":"352_CR318","doi-asserted-by":"publisher","first-page":"116347","DOI":"10.1016\/j.bios.2024.116347","volume":"258","author":"J Kim","year":"2024","unstructured":"Kim J, Son HY, Lee S, Rho HW, Kim R, Jeong H, et al. Deep learning-assisted monitoring of trastuzumab efficacy in HER2-overexpressing breast cancer via SERS immunoassays of tumor-derived urinary exosomal biomarkers. Biosens Bioelectron. 2024;258:116347. https:\/\/doi.org\/10.1016\/j.bios.2024.116347.","journal-title":"Biosens Bioelectron"},{"issue":"4","key":"352_CR319","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","volume":"12","author":"E Castellanos","year":"2017","unstructured":"Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(4):612\u201323. https:\/\/doi.org\/10.1016\/j.jtho.2016.12.014.","journal-title":"J Thorac Oncol"},{"issue":"21","key":"352_CR320","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMe2311559","volume":"389","author":"YL Wu","year":"2023","unstructured":"Wu YL, Zhou Q. Combination therapy for EGFR-mutated lung cancer. N Engl J Med. 2023;389(21):2005\u20137. https:\/\/doi.org\/10.1056\/NEJMe2311559.","journal-title":"N Engl J Med"},{"issue":"9","key":"352_CR321","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.7150\/thno.93962","volume":"14","author":"W Jin","year":"2024","unstructured":"Jin W, Zhang Y, Zhao Z, Gao M. Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression. Theranostics. 2024;14(9):3439\u201369. https:\/\/doi.org\/10.7150\/thno.93962.","journal-title":"Theranostics"},{"issue":"11","key":"352_CR322","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918\u201332. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"issue":"10129","key":"352_CR323","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(18)30422-7.","journal-title":"Lancet"},{"issue":"1","key":"352_CR324","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-023-00914-7","volume":"13","author":"K Shah","year":"2023","unstructured":"Shah K, Nasimian A, Ahmed M, Al Ashiri L, Denison L, Sime W, et al. PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia. Blood Cancer J. 2023;13(1):139. https:\/\/doi.org\/10.1038\/s41408-023-00914-7.","journal-title":"Blood Cancer J"},{"issue":"1","key":"352_CR325","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/1078-0432.CCR-20-2415","volume":"27","author":"P Johannet","year":"2021","unstructured":"Johannet P, Coudray N, Donnelly DM, Jour G, Illa-Bochaca I, Xia Y, et al. Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clin Cancer Res. 2021;27(1):131\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2415.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"352_CR326","doi-asserted-by":"publisher","first-page":"10390","DOI":"10.1038\/s41467-024-54771-4","volume":"15","author":"Z Cai","year":"2024","unstructured":"Cai Z, Apolinario S, Baiao AR, Pacini C, Sousa MD, Vinga S, et al. Synthetic augmentation of cancer cell line multi-omic datasets using unsupervised deep learning. Nat Commun. 2024;15(1):10390. https:\/\/doi.org\/10.1038\/s41467-024-54771-4.","journal-title":"Nat Commun"},{"issue":"10","key":"352_CR327","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1158\/1078-0432.CCR-16-0895","volume":"23","author":"N Baran","year":"2017","unstructured":"Baran N, Konopleva M. Molecular pathways: Hypoxia-activated prodrugs in cancer therapy. Clin Cancer Res. 2017;23(10):2382\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0895.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"352_CR328","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","volume":"18","author":"WD Tap","year":"2017","unstructured":"Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18(8):1089\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(17)30381-9.","journal-title":"Lancet Oncol"},{"issue":"2","key":"352_CR329","doi-asserted-by":"publisher","first-page":"nwae451","DOI":"10.1093\/nsr\/nwae451","volume":"12","author":"P Zhang","year":"2025","unstructured":"Zhang P, Wang X, Cen X, Zhang Q, Fu Y, Mei Y, et al. A deep learning framework for in silico screening of anticancer drugs at the single-cell level. Natl Sci Rev. 2025;12(2):nwae451. https:\/\/doi.org\/10.1093\/nsr\/nwae451.","journal-title":"Natl Sci Rev"},{"issue":"24","key":"352_CR330","doi-asserted-by":"publisher","first-page":"e2102092","DOI":"10.1002\/advs.202102092","volume":"8","author":"Z Ye","year":"2021","unstructured":"Ye Z, Chen F, Zeng J, Gao J, Zhang MQ. Scaffcomb: a phenotype-based framework for drug combination virtual screening in large-scale chemical datasets. Adv Sci. 2021;8(24):e2102092. https:\/\/doi.org\/10.1002\/advs.202102092.","journal-title":"Adv Sci"},{"issue":"W1","key":"352_CR331","doi-asserted-by":"publisher","first-page":"W258","DOI":"10.1093\/nar\/gkaf366","volume":"53","author":"S Lin","year":"2025","unstructured":"Lin S, Tu C, Hu R, Wang H, Dong Z, Luo H, et al. Dr. Kinase: predicting the drug-resistance hotspots of protein kinases. Nucleic Acids Res. 2025;53(W1):W258\u201365. https:\/\/doi.org\/10.1093\/nar\/gkaf366.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"352_CR332","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","volume":"19","author":"JP Friedmann Angeli","year":"2019","unstructured":"Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405\u201314. https:\/\/doi.org\/10.1038\/s41568-019-0149-1.","journal-title":"Nat Rev Cancer"},{"issue":"7782","key":"352_CR333","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1.","journal-title":"Nature"},{"issue":"21","key":"352_CR334","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020.","journal-title":"Cell"},{"issue":"2","key":"352_CR335","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-021-00301-6","volume":"21","author":"A Honkala","year":"2022","unstructured":"Honkala A, Malhotra SV, Kummar S, Junttila MR. Harnessing the predictive power of preclinical models for oncology drug development. Nat Rev Drug Discov. 2022;21(2):99\u2013114. https:\/\/doi.org\/10.1038\/s41573-021-00301-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"352_CR336","doi-asserted-by":"publisher","first-page":"447","DOI":"10.20517\/cdr.2019.005","volume":"2","author":"M Michaelis","year":"2019","unstructured":"Michaelis M, Wass MN, Cinatl J. Drug-adapted cancer cell lines as preclinical models of acquired resistance. Cancer Drug Resist. 2019;2(3):447\u201356. https:\/\/doi.org\/10.20517\/cdr.2019.005.","journal-title":"Cancer Drug Resist."},{"key":"352_CR337","doi-asserted-by":"publisher","first-page":"1289756","DOI":"10.3389\/fonc.2023.1289756","volume":"13","author":"G Adriani","year":"2023","unstructured":"Adriani G, Cappello P, Lovisa S. Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance. Front Oncol. 2023;13:1289756. https:\/\/doi.org\/10.3389\/fonc.2023.1289756.","journal-title":"Front Oncol"},{"issue":"3","key":"352_CR338","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7150\/thno.7323","volume":"4","author":"AM LeBeau","year":"2014","unstructured":"LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, et al. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 2014;4(3):267\u201379. https:\/\/doi.org\/10.7150\/thno.7323.","journal-title":"Theranostics"},{"key":"352_CR339","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.11.005","volume":"24","author":"NG Alkema","year":"2016","unstructured":"Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resist Updat. 2016;24:55\u201369. https:\/\/doi.org\/10.1016\/j.drup.2015.11.005.","journal-title":"Drug Resist Updat"},{"issue":"6378","key":"352_CR340","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920\u20136. https:\/\/doi.org\/10.1126\/science.aao2774.","journal-title":"Science"},{"issue":"6257","key":"352_CR341","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311. https:\/\/doi.org\/10.1126\/science.aad0095.","journal-title":"Science"},{"issue":"46","key":"352_CR342","doi-asserted-by":"publisher","first-page":"31046","DOI":"10.1021\/acsomega.1c04204","volume":"6","author":"L Xin","year":"2021","unstructured":"Xin L, Xiao W, Che L, Liu J, Miccio L, Bianco V, et al. Label-free assessment of the drug resistance of epithelial ovarian cancer cells in a microfluidic holographic flow cytometer boosted through machine learning. ACS Omega. 2021;6(46):31046\u201357. https:\/\/doi.org\/10.1021\/acsomega.1c04204.","journal-title":"ACS Omega"},{"issue":"12","key":"352_CR343","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ccell.2023.10.008","volume":"41","author":"S Lambo","year":"2023","unstructured":"Lambo S, Trinh DL, Ries RE, Jin D, Setiadi A, Ng M, et al. A longitudinal single-cell atlas of treatment response in pediatric AML. Cancer Cell. 2023;41(12):2117-35 e12. https:\/\/doi.org\/10.1016\/j.ccell.2023.10.008.","journal-title":"Cancer Cell"},{"issue":"7955","key":"352_CR344","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-023-05795-1","volume":"616","author":"D Zhang","year":"2023","unstructured":"Zhang D, Deng Y, Kukanja P, Agirre E, Bartosovic M, Dong M, et al. Spatial epigenome-transcriptome co-profiling of mammalian tissues. Nature. 2023;616(7955):113\u201322. https:\/\/doi.org\/10.1038\/s41586-023-05795-1.","journal-title":"Nature"},{"issue":"1","key":"352_CR345","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12672-025-02106-0","volume":"16","author":"X Han","year":"2025","unstructured":"Han X, Ma Q, Chang R, Xin S, Zhang G, Wang R, et al. Identification of m(6)A-modified gene signatures in lung adenocarcinoma tumorigenesis and their potential role in drug resistance. Discover Oncol. 2025;16(1):392. https:\/\/doi.org\/10.1007\/s12672-025-02106-0.","journal-title":"Discover Oncol"},{"issue":"6","key":"352_CR346","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.molcel.2018.08.011","volume":"71","author":"J Wei","year":"2018","unstructured":"Wei J, Liu F, Lu Z, Fei Q, Ai Y, He PC, et al. Differential m(6)A, m(6)A(m), and m(1)A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell. 2018;71(6):973-85 e5. https:\/\/doi.org\/10.1016\/j.molcel.2018.08.011.","journal-title":"Mol Cell"},{"issue":"9","key":"352_CR347","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2017.14.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00352-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00352-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00352-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:59:18Z","timestamp":1763369958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00352-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":347,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00352-w","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors state that there is no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}